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ABSTRACT 
Forensic practitioners have long sought efficient and reliable means for identifying 
those samples that are best suited for successful genetic profiling. Traditional serological 
screening methodologies rely upon enzyme activity and antibody-based serological tests. 
These tests can be consumptive, laborious and costly while reliance on antibody-based 
serological testing can be prone to error.  Positive results resulting from non-target 
biological fluids, the potential for cross-reactivity and non-specific binding events yield 
merely presumptive results.  This has led forensic biologists to omit serological testing, at 
least in the case of sexual assault kit samples, in favor of Y-Screen assays.  While these Y-
Screen approaches achieve rapid screening of samples for the presence of a detectible male 
DNA, they do not provide any serological information and therefore lack critical 
investigative/biological context. 
A more sensitive and accurate technology for the confirmatory identification of 
biological fluids would greatly bolster the weight of serological evidence presented in court 
and assist with more informed sample prioritization.  A particularly promising approach 
combines high-specificity protein biomarkers with a target-ion mass spectrometry. 
Applying  absolute  quantitation  of  protein targets in the biomarker panel 
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will enable forensic practitioners to make fuller use of serological information in their 
decision making on downstream analyses in order to improve the successful analysis of 
challenging sexual assault samples. 
This research demonstrated the prevalence of false-positive results associated with 
antibody-based serological methods, developed and validated a multiplex targeted-ion 
mass spectrometry-based assay for the identification of six forensically relevant biological 
fluids, demonstrated improved sensitivity and specificity of mass-spectrometry based body 
fluid identification as compared to traditional techniques, developed a modified assay for 
seminal fluid compatible with sexual assault kit evidence and evaluated the relationship 
between quantitative levels of target seminal fluid peptides and the ability to generate Y-
STR profiles.   These results provide the forensic and criminal justice communities with a 
powerful tool to aid in the criminal investigation of violent crimes.  
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CHAPTER 1:  INTRODUCTION 
1  Introduction 
Forensic serology is the study of blood, saliva, semen and other bodily fluids in 
relation to legal matters [1].  Biological fluid detection and identification provides 
important contextual information to a forensic investigation.  While genetic testing can 
help to establish from whom DNA may have come, only serological testing can provide an 
indication of the body fluid or tissue from which a DNA profile may have originated [2].  
There exist myriad examples of how the unambiguous identification of biological fluids 
can be critical to an investigation.  Take for example the analysis of a victim’s clothing 
from an alleged sexual assault.  The identification of biological stains such as semen 
through forensic serological techniques may render more probable the inference that a 
sexual act occurred while a match between the DNA profile generated from that stain and 
a suspect’s reference profile helps to establish a link between the suspect and victim. Both 
pieces of information can be presented in court to corroborate allegations of sexual assault 
by a given suspect. The ability to obtain the most probative value from a biological stain 
in a criminal investigation, therefore, requires both the development of an interpretable 
DNA profile and the identification of the biological substance from which the profile 
originated.  
2 
1.1 Past and Current Serological Techniques 
Current forensic tools for the identification of biological fluids are based on the 
same fundamental methods that have been employed for much of the history of forensic 
science. Namely, these are chemical reactions involving components of a body fluid; 
detection of enzymatic activity (typically through colorimetric reactions) characteristic of 
a body fluid; immunological binding to antigens that are characteristic of a body fluid or, 
in the case of semen, direct visualization of spermatozoa by microscopy.  All of these 
techniques have value to forensic investigations; however, they also suffer from a variety 
of substantial test-specific limitations.  These tests as they apply to the identification of 
blood, semen, saliva, urine, vaginal fluid and feces will be outlined below as will their 
advantages and limitations.  
1.1.1  Presumptive Detection of Blood 
Bloodstains are commonly submitted for analysis as part of criminal investigations.  
Blood as a matrix is composed of a watery, protein rich fluid called plasma and a cellular 
component comprised of erythrocytes, leukocytes and thrombocytes.  Erythrocytes are 
responsible for the transport of oxygen throughout the body and mainly consist of the 
metalloprotein hemoglobin.  Given its high abundance in blood, the hemoglobin protein 
has long served as the primary target for most blood detection reactions.  Normal adult 
hemoglobin consists of four globular polypeptide chains (2α chains and 2β chains), each 
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of which is tightly associated with a non-protein heme group, an iron ion held in a 
porphyrin ring.  
Currently, the most common form of presumptive tests for suspected bloodstains 
are chemical color reaction based assays as exemplified by the phenolphthalein or Kastle-
Meyer test. This reaction takes advantage of the peroxidase-like activity of heme.  The iron 
in heme readily transitions between the ferrous and ferric state.  This movement of 
electrons helps catalyze a reaction with a peroxide group (most commonly in the form of 
hydrogen peroxide) to create free radical species.  These free radicals then react with an 
indicator compound (e.g., phenolphthalin), which becomes oxidized to phenolphthalein 
(Figure 1) generating a bright pink color indicative of a positive result (Figure 2) [3].  
Additional chemical color tests for blood that follow the same reaction mechanism employ 
tetramethylbenzidine (used commercially in the Hemastix® test), orthotolidine, 
leucomalachite green and luminal.  These assays, while extremely sensitive, are not 
specific.  Strong chemical oxidants (such as hypochlorite ions in bleach and household 
cleaners or metal salts like copper and nickel salts) can directly oxidize an indicator 
compound to produce a color change in the absence of heme.  Additionally, there are many 
plant tissues (i.e.,  potato, tomato, red onion, horseradish) that possess peroxidase-like 
activity that will also catalyze this reaction [4].  Additionally, strong reductants, when 
present, may cause false negative results [3]. 
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Figure 1:  Chemical reaction of underlying the phenolphthalein assay (Kastle-Meyer 
reaction) for the presumptive detection of blood.  Phenolphthalin (colorless) is oxidized in 
the presence of hydrogen peroxide and heme to produce phenolphthalein which appears 
pink.   
Figure 2:  Photograph of phenolphthalein assay results.  The swab on the left is an example 
of a negative reaction. The swab on the right provides an example of a positive reaction.    
Microcrystal assays have also been historically used for bloodstain detection.  
These tests apply chemicals to suspected bloodstains to form characteristic heme crystals.  
In 1853, the Teichmann crystal assay was developed. In this assay, glacial acetic acid and 
salts (potassium bromide, potassium chloride and potassium iodide) were used to react with 
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hematin to form characteristic brown rhomboid crystals [3].  In 1912, the Takayama 
method in which heme was combined with sodium hydroxide, saturated glucose, pyridine 
and water was published. This method produced characteristic feathery reddish/purple 
crystals, comprised of pyridine ferroprotoporphyrin ring structures that could be readily 
viewed under polarized light [1].  While more specific than the catalytic color reactions for 
blood, these microcrystalline tests produced positive results with heme containing 
molecules  other   than  hemoglobin,   such  as  bacterial   catalases  and   peroxidases [5].  
Additionally, in cases where dilute or only trace quantities of evidence are available, crystal 
assays were found to lack the sensitivity required for the reliable detection of blood in many 
forensic contexts. 
Immunological reactions are also commercially available for blood detection.  
These include Hexagon OBTI (Human Gesellschaft fur Biochemica), HemDirect 
(Seratec®), ABAcard HemaTrace® (Abacus Diagnostics) and RSIDTM Blood (Independent 
Forensics).  The first three detect hemoglobin in blood while RSIDTM Blood targets 
glycophorin A on the surface of red blood cells.  Glycophorin A is a transmembrane protein 
responsible for cell-cell binding interactions [6].  All four of these methods are 
immunochromatographic assays.  Therefore, they function in a similar manner and are 
subject to similar limitations.  
In an immunochromatographic assay, labeled (e.g., colloidal gold conjugated) 
mobile-phase antibodies specific to a protein antigen (i.e., a biomarker) of interest are 
localized to a sample well within an immunochromatographic assay cartridge.  When an 
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aqueous sample extract is added, the target antigen binds with these antibodies and the 
complex diffuses down a nitrocellulose membrane.  Immobilized at a test site in the 
membrane are additional antibodies for a second epitope on the target protein.  This binds 
to the antigen-antibody complex and produces a line to indicate a positive result based on 
the accumulation of labeled antibodies at the test site.  An internal control consisting of 
immobilized anti-immunoglobulin antibodies that are specific to the antibodies contained 
on the dye-labeled mobile-phase particles form the sample well is also built into the assay. 
The internal control antibodies are patterned into an immobilized control line further down 
the test strip (Figure 3).  Test results are only considered valid when the line in the control 
zone can be observed.  A positive result therefore appears as at least two colored lines, one 
at the test zone and one at the control zone, whereas a negative test result appears as a 
single line at the control zone (Figure 4).  The specificity of some of these assays for 
hemoglobin and glycophorin A is such that they are capable of distinguishing between 
human blood (and that of higher order primates) and the blood of other nonhuman species.  
Therefore, they can be used not only for presumptive blood detection but also for 
presumptive species categorization.  
While sensitive, fast and easy to use, these assays can be costly and suffer from a 
lack of body fluid specificity.  Target protein biomarkers present at lower concentrations 
in other biological fluids can also generate a positive reaction [7].  For example, the 
sensitivity of the ABAcard HemaTrace® can be as low as 0.07 μg/mL of hemoglobin, 
making the assay more sensitive than chemical color reactions for blood.  As a result, 
however, the test has been shown to produce positive results with seminal fluid stains, and 
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oral, vaginal, anal, and rectal swabs.  At this level of sensitivity, it is thought that the assay 
is detecting very low amounts of hemoglobin in these non-target fluids; thereby generating 
false positive reactions in regard to the biological fluid being targeted [3].  Unpredictable 
cross-reactivity with non-target molecules having similar conformational epitopes is also 
possible as are non-specific binding events due to extremes of pH or other sample-specific 
chemical compounds.  Environmental contaminants also have the possibility of interfering 
with antibody binding [7].  Degraded samples will not work with these assays due to loss 
of conformational integrity of the target protein.  Additionally, at high concentrations of 
target antigen, these tests suffer from a phenomena called the high-dose hook effect, 
leading to false negative reactions [8]. 
Figure 3:  Lateral Flow Immunochromatographic Test Strip Design 
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Figure 4:  Immunochromatographic Assay depicting a positive (top) and negative (bottom) 
reaction.  (a) In the sample well the target antigen (hemoglobin or glycophorin A in the 
case of blood assays) present in the sample binds to the mobile phase antibodies conjugated 
to colloidal gold particles.  (b)  At the test zone, the colloidal gold conjugated antigen-
antibody complex to binds to immobilized target antigen antibodies to form a labeled 
antibody antigen antibody sandwich.  If the sample is positive, colloidal gold conjugated 
antigen-antibody complex will start to accumulate in these sandwich formations forming a 
visible colored line at the test zone.  If the sample is negative, the antigen-free colloidal 
gold conjugated antibodies will flow past the test zone.  (c)  At the control zone, the 
antigen-free colloidal gold conjugated antibodies from the sample well will bind to 
immobilized anti-immunoglobulin antibodies forming a visible colored line at the control 
zone.   (d) A positive test result has a line at both the test and control zones.  A negative 
test has no line at the test zone and a line at the control zone.   
More historical methods of species identification also employed antigen-antibody 
interactions but were based on the visualization of a precipitation reaction following 
immunodiffusion. The most basic example of this approach was the ring assay in which a 
sample extract, containing target antigens if positive, is layered on top of an antisera 
solution without mixing.  Both antigen and antibody will diffuse (double immunodiffusion) 
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toward each other.  In a positive reaction, a white precipitate forms at the interface of the 
two layers.  Another example of a double immunodiffusion assay is the Ouchterlony assay.  
This assay is performed by punching a series of wells into an agarose gel matrix.  Antisera 
is loaded into one well and sample extracts possibly containing target antigens are loaded 
into surrounding wells.  The gel is then incubated to allow for the diffusion of both antigen 
and antibody through the gel matrix.  When target antigens are present, a precipitate line 
will form between the sample well and the well containing antisera (Figure 5).  In lieu of 
passive diffusion, an electric field can be applied to the gel such as during cross-over 
electrophoresis. This serves to drive antigens across an agar gel resulting in enhanced 
sensitivity. As with the ring and Ouchterlony assays, a positive reaction is denoted by 
formation of a visible precipitate.   
Figure 5:  (a)  Diagram of the Ouchterlony assay.  (b)  Two rosettes punched into an agarose 
gel.  In the central well of each rosette, antisera is loaded.  In the rosette to the right, the 
top well was loaded with a positive control; the bottom well was loaded with a negative 
control and the two side wells were loaded with sample extract.  Both samples and the 
positive control produced a positive reaction as indicated by the visible white precipitate 
line.  The negative control is negative as it lacks a visible precipitate between it and the 
antisera well.    
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1.1.2  Presumptive and Confirmatory Detection of Semen 
Semen is comprised of a cellular component, spermatozoa (sperm cells), leukocytes 
and epithelial cells, as well as a fluid portion.  During spermatogenesis, spermatozoa are 
formed in seminiferous tubules in the testes.  Spermatozoa are then transported to the 
epididymis where they mature, a process that takes approximately three months.  During 
ejaculation, sperm cells leave the epididymis through the vas deferens where they can 
ultimately join with secretions from glandular tissues.  An average ejaculation produces 2-
5 mL of semen containing 107 to 108 spermatozoa per milliliter. Sperm cells account for 
only 1-5% of the total ejaculate volume [9].  
Human spermatozoa are comprised of three regions, the head, the midpiece, and 
the tail.  The head contains the nucleus which contains a single set of chromosomes from 
the male.  The acrosomal cap surrounds the very tip of the head.  The acrosomal cap 
contains lytic enzymes that aid in the digestion of the outer membrane of the ovum, 
allowing for sperm penetration.  The midsection connects the head to the tail.  This is where 
the mitochondria that generate ATP to provide energy for tail movement are localized.  The 
tail itself contains microfilaments that contract to provide forward motion.  
Seminal plasma is a complex fluid mixture made up of contributions from the 
seminal vesicle, prostate and bulbourethral glands.  Pre-ejaculatory fluid consists almost 
entirely of secretions from the bulbourethral gland.  This can contain traces of acid 
phosphatase and prostate specific antigen.  Less frequently, spermatozoa are observed and 
these are thought to be due to carryover from a prior ejaculation.  The bulbourethral gland 
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secretes mainly galactose used for energy and mucus production.  Secretions from the 
prostate gland account for approximately 30% of the ejaculate and include the enzyme acid 
phosphatase, prostate specific antigen, citric acid, proteolytic enzymes and zinc.  Both acid 
phosphatase and prostate specific antigen are protein markers that are typically targeted for 
the presumptive detection of seminal fluid.  The seminal vesical contributes 65-75% of the 
overall semen volume and secretes semenogelin proteins, flavins, fructose and 
prostaglandins [10, 11].  Flavins are notable for their contribution to semen’s ability to 
fluoresce under ultraviolet light – a property which is used to search for possible seminal 
stains. Semenogelin I and II serve as additional targets for the immunochromatographic 
detection of seminal fluid.  
Chemical reaction-based assays such as the Barberio and Florence crystal tests have 
also been used historically for the presumptive detection of seminal fluid.  Due to their lack 
of specificity and reproducibility however, they have been replaced with tests targeted to 
enzyme activity and antibody-based detection of protein antigens.  As previously stated, 
prostatic fluid secretions include the enzyme acid phosphatase which has long served as a 
presumptive marker for the detection of seminal fluid.  Prostatic acid phosphatase cleaves 
phosphate from substrates such as α-naphthol phosphate.  The resulting α-naphthol 
undergoes an azo coupling reaction to form a pink/purple colored product indicative of a 
positive reaction (Figure 6)  [12].    As this reaction requires enzymatic activity, loss of 
this activity over time due to such factors as microbial-associated protein degradation, 
exposure to extremes of temperature and/or pH or inhibitory chemical agents can limit the 
sensitivity and the time period during which this assay is useful. 
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While generally sensitive, this test is presumptive in nature as positive results can 
also be generated by bacteria present in vaginal secretions as well as by endogenous acid 
phosphatase produced by cervical epithelial cells.  False positive results can also be 
obtained with a variety of  food products [13].  Several other acid phosphatase isoenzymes 
have also been identified in human tissues aside from prostatic acid phosphatase.  These 
include erythroid acid phosphatase, lysosomal acid phosphatase, macrophage acid 
phosphatase, and testicular acid phosphatase [3]. Elevated concentrations of acid 
phosphatase in serum is seen (and used diagnostically) in patients with prostate cancer.  
Figure 6:  Acid phosphatase overlay used to detect seminal fluid stains on undergarments 
such as those submitted in cases of alleged sexual assault.  The purple/pink color indicates 
the presumptive presence of acid phosphatase.   
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Historically, the Ouchterlony assay as well as enzyme-linked immunosorbent 
assays (ELISA) were used to detect seminal fluid protein markers such as prostate specific 
antigen.  During an ELISA assay for prostate specific antigen (PSA) which is also known 
as p30, an anti-PSA antibody was bound to the bottom of wells on a polystyrene plate.  
Sample extracts to be tested for the possible presence of PSA were then added to the wells.  
Samples containing PSA allowed formation of a complex between the anti-PSA antibody 
and the PSA antigen.  A second anti-PSA antibody for a different epitope on the target 
antigen was then added. This resulted in the formation of an antibody-antigen-antibody 
sandwich in wells containing extracts from positive samples.  An enzyme-conjugated anti-
immunoglobulin antibody targeted to that second antibody in the sandwich was then added 
to each assay well. This was designed to bind to the sandwich complex in wells with 
extracts that were positive for PSA.  The wells were then washed to remove any unbound 
anti-immunoglobulin antibodies. Detection of any enzyme-conjugated anti-
immunoglobulin antibodies that remained bound to the sandwich complex (typically by 
addition of an appropriate substrate for the conjugated enzyme) indicated a presumptive 
positive result (Figure 7).  
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Figure 7:  ELISA assay for prostate specific antigen (PSA).  (a) anti-PSA antibody 
immobilized to the bottom of a well on a polystyrene plate.  (b) PSA antigen from a positive 
sample extract is added.  (c) A second anti-PSA antibody for a different epitope is added 
forming an antibody-antigen-antibody sandwich.  (d) enzyme-conjugated anti-
immunoglobulin antibodies which are expected to bind only in positive wells allows for 
detection of positive results.   
In recent years, however, these techniques have been replaced by alternative 
antigen-antibody assays based on immunochromatographic cartridges. The ABA p30 
(Abacus Diagnostics), PSA SemiQuant® (Seratec), and RSIDTM Semen (Independent 
Forensics) are three examples of commercially available assays for seminal fluid.  The 
ABA p30 and PSA SemiQuant® cartridges target p30/PSA while the RSIDTM Semen 
targets semenogelin, a protein secreted by the seminal vesicle.  Contrary to its name, PSA 
is not specific to the male prostate.  It can also be found in female vaginal secretions [14], 
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amniotic fluid [15], breast milk  [16], and urine [17]. False positive results have also been 
observed with semen-free vaginal (Figure 8) and postmortem rectal swabs  [18].  Similarly, 
semenogelin has been identified in kidney, colon and tracheal tissues as well as the sera of 
lung cancer patients [3]. Moreover, non-specific binding events have been readily observed 
to occur in the presence of organic acids.  
(A) 
(B) 
Figure 8:  Examples of putative false positive reactions from semen-free vaginal swabs 
targeting semenogelin (A) and prostate specific antigen (B).  Each set of four cartridges 
includes one positive control and three test samples. Test lines indicating the presumptive 
presence of seminal fluid proteins in semen-free vaginal swabs ranged from faint to 
moderately strong.  
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Cellular components from a suspected seminal stain can be identified by 
microscopy.  Visual detection of human spermatozoa by a trained analyst is considered to 
be confirmation of the presence of semen.  Staining techniques such as the Christmas tree 
stain (nuclear fast red and picroindigocarmine) or Sperm HyLiterTM (Independent 
Forensics) are commonly used to facilitate the visualization of sperm cells (Figures 9-10).  
Sperm HyLiterTM incorporates a fluorochrome-conjugated antibody into the staining 
process. This antibody is targeted to a nuclear membrane protein in spermatozoa [19].  The 
greatest advantage to microscopic visualization techniques for the identification of semen 
is its confirmatory nature.  However, the staining process and visualization of samples can 
be time consuming.  Sperm HyLiterTM can reduce the search time needed to locate sperm 
but it produces poor spermatozoa morphology with degraded samples.  Additionally, these 
techniques are not applicable to cases involving males who are vasectomized or suffer from 
aspermia.    
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Figure 9:  Spermatozoa visualized via light microscopy following the addition of Christmas 
tree staining (nuclear fast red and picroindigocarmine).   
Figure 10:  Spermatozoa visualized via Sperm HyLiter staining in combination with 
fluorescent microscopy (sperm and epithelial cells visualized under the DAPI filter 
(LEFT), sperm cells visualized under the FITC filter (CENTER) and sperm and epithelial 
cells visualized with an overlay (RIGHT)).   
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1.1.3  Presumptive Detection of Saliva 
Saliva is composed primarily of water but also contains electrolytes, buffers, 
glycoproteins, antibodies and enzymes.  Approximately 1.0-1.5 L of saliva is produced 
daily by both serous and mucous acini cells, the basic secretory units of the salivary glands.  
The three major salivary glands, the parotid, submaxillary and sublingual, produce 
approximately 90% of saliva while the remaining 10% is produced by the minor salivary 
glands.  Saliva serves many roles in the body; it acts as a lubricant and binder to protect 
the esophagus from masticated food, solubilizes dry food so that it can be tasted, flushes 
the oral cavity of food and debris for oral hygiene and initiates starch digestion.  The 
enzyme α-amylase is the component of saliva responsible for cleaving the glycosidic bonds 
of polysaccharide carbohydrates; thereby breaking them down into smaller oligo- and 
monosaccharide molecules.  Due to its abundance in salivary secretions, the detection of 
α-amylase serves as the basis for the presumptive presence of saliva.    
Several types of amylases have been characterized that differ based on their 
mechanism of hydrolysis.  The faster acting α-amylases require calcium as a cofactor and 
act at random locations along a polysaccharide carbohydrate chain producing glucose and 
maltose molecules.  Mostly found in mammals, two isoforms of α-amylase exist – salivary 
and pancreatic amylase.  Encoded by the Amy1 and Amy2 loci respectively, the amino acid 
sequences of these isoforms are highly homologous and therefore difficult to distinguish 
from each other.  Found mostly in plants, fungal and bacterial sources, β-amylase moves 
from the non-reducing end of polysaccharide carbohydrate catalyzing the hydrolysis of 
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every other α-1,4 glycosidic bond to yield maltose molecules [20].  A third isoform, γ-
amylase, hydrolyzes α-1,6 glycosidic linkages and unlike the other isoforms of amylase, 
will continue to function in acidic environments [21].  
A common presumptive test for saliva is an enzyme activity-based test for amylase 
called the starch-iodine radial diffusion test.  For this assay, starch is incorporated into a 
gel matrix.  Suspected saliva stains are then allowed to incubate within wells in this matrix. 
Through passive diffusion, the amylase in saliva will cleave starch molecules into 
oligosaccharides within the gel matrix surrounding the well.  Iodine is then used to stain 
the gel as iodine reacts strongly with amylose in starch to form a dark blue complex.  Any 
clear areas around wells of the gel indicate a lack of starch and therefore the presence of 
amylase activity.  The size of the clear “halo” around the well can be correlated to the 
amount of amylase activity in a sample (Figure 11).  This test, however, is not specific to 
α-amylase as it will also react with β-amylase, which as previously indicated, is present in 
plant and bacterial sources.  In addition, small amounts of amylase enzyme present in body 
fluids other than saliva, e.g., breast milk [22], sweat, tears, semen [23], vaginal fluid and 
feces [24] are also capable of yielding positive results.. 
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Figure 11:  Starch radial diffusion test.  The clear wells indicate the presence of amylase.  
The larger the radius of the clear area around the well, the greater the concentration of 
amylase activity.     
Additional assays that test for amylase activity include the Phadebas® test (Magel 
Life Sciences) and the SALIgAE® test (Abacus Diagnostics) [25].  These are colorimetric 
assays that utilize insoluble dye-labeled amylase substrates.  When a suspected saliva stain 
is assayed, amylase activity will cleave the dye-labeled amylase substrates, forming smaller 
soluble saccharide molecules.  This allows for dye solubilization and thus color 
development indicating the presence of amylase activity  (Figure 12).    These assays are 
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again considered presumptive as they are not specific to human salivary α-amylase and 
have the potential to react with the variety of substances and non-saliva body fluids listed 
above which also contain amylase. 
Figure 12:  The smear of pale blue in the center of the substrate indicates the presumptive 
presence of saliva using the Phadebas® test.   
Commercially available immunochromatographic assays for saliva include the 
RSIDTM Saliva (Independent Forensics) test [26]. This assay employs monoclonal anti-
human salivary α-amylase antibodies conjugated to colloidal gold particles (typically) 
within the sample well. A second monoclonal anti-human salivary α-amylase antibody is 
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immobilized at the test zone of the cartridge.  Positive results from non-saliva samples 
reported in the literature for this assay include breast milk, urine, feces, semen and rat saliva 
[23, 26, 27].  ELISA as well as the Ouchterlony assays, both described previously, can also 
be used to detect human salivary α-amylase as well as statherin which is another saliva 
biomarker protein [28, 29].  As with any antibody-based assay, unpredictable cross-
reactivity with non-target molecules having similar conformational epitopes is a concern 
as are non-specific binding events due to extremes of pH or other sample-specific chemical 
compounds which may lead to false positive reactions.  
1.1.4  Presumptive Detection of Urine and Fecal Matter 
Urine is composed primarily of water but also contains organic molecules, ions, 
leukocytes and epithelial cells.  The kidneys are responsible for the formation of urine 
which removes the waste products of cellular metabolism.  Urea, an end-product of protein 
degradation, is one of the most abundant waste components of urine.  Creatinine, a product 
of muscle metabolism, is another major waste product found in urine.  A number of 
chemical reaction-based assays as well as enzyme-activity based assays have been 
developed to test for the presence or both urea and creatinine.  
Urea can be detected with the Nessler’s reagent.  In this assay, urease is used to 
catalyze the hydrolysis of urea to liberate ammonia and carbon dioxide.  The production of 
ammonia is detected with Nessler’s reagent (potassium hydroxide, mercuric iodide and 
potassium iodide) through the formation of an orange/brown precipitate. Ammonia 
formation following urease application has also historically been detected using 
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bromthymol blue, an acid base indicator that turns blue in the presence of urine. Manganese 
and silver nitrates, which turn black in the presence of urine, have also been used.  
Alternatively, para-dimethylaminocinnamaldehyde (DMAC) has been used to directly 
detect urea based on the formation of a pink/red color in its presence.  However, none of 
these methods described are specific to urine.  Other bodily fluids namely vaginal 
secretions, semen, saliva, and sweat can all produce positive reactions [30].  Historical use 
of microscopic crystal assays for the detection of urea and converted urea nitrate crystals 
can also be found in the literature [5].  
Creatinine can be detected using a colorimetric reaction called the Jaffe color test.  
During this test, the addition of sodium hydroxide and picric acid are used to convert 
creatinine to creatinine picrate which forms a yellow/orange precipitate.  Recently, a test 
cartridge called Uritrace (Abacus Diagnostics) has become commercially available for the 
detection of creatinine. This test also employs a colorimetric mechanism of action.  The 
Salkowski test was another historically used colorimetric reaction in which sodium 
nitroprusside reacted with creatinine upon heating to form a blue product.  As with other 
urine assays, these reactions suffered from specificity limitations. While found in higher 
concentrations in urine, creatinine is not specific to urine.  During muscle cell metabolism 
creatinine is formed through the metabolism of phosphocreatine through an intermediary 
and creatine released into the blood.  From there it is filtered by the kidneys into urine for 
excretion.  As a result, it can be detected in blood as well as semen.  Additionally, the 
amount of creatinine present in the urine is directly proportional to an individual’s muscle 
mass resulting in high interindividual variability in detection sensitivity.  
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RSIDTM Urine (Independent Forensics) targets the most abundant protein in urine, 
uromodulin or Tamm-Horsfall glycoprotein.  Tamm-Horsfall glycoprotein is synthesized 
in the epithelial cells of the loop of Henle (ansa nephroni) and secreted into the lumen.  
Historically, an ELISA assay was used to detect Tamm-Horsfall glycoprotein.  As with 
most of the other currently employed serological tests mentioned above, however, these 
assays are presumptive in nature as urine from non-human species as well as synthetic 
urine and a number of other commercial products have been found to produce positive 
reactions (Figure 13). 
Figure 13:  False positive result using an RSID TM Urine assay following the addition of 
Coca Cola in the absence of urine.   
Fecal material is comprised mostly of undigested food, water and bacteria.  The test 
for fecal matter, known as the Edelman test, identifies the presence of urobilinogen, a 
product of bilirubin reduction formed in the intestines.  Mercuric chloride has historically 
been used to oxidize urobilinogen to urobilin which in turn forms a zinc-urobilin complex 
in the presence of alcoholic zinc chloride.  This chelated complex appears candy apple 
green when viewed under UV light (Figure 14). This test cannot distinguish between 
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human and other mammalian fecal material.  Additionally, as urobilin is also present in 
urine (albeit at lower concentrations), positive results can also be obtained with urine 
samples.  Therefore, this test is presumptive in nature.  Additionally, visualization of the 
chelated complex with UV light can be obscured by the presence of fats [3].  
Figure 14:  A positive result (LEFT) and negative result (RIGHT) using the urobilinogen 
test for fecal matter.   
1.1.5  Vaginal Secretions and Menstrual Fluid 
Currently, there are no tests routinely used or that are commercially available for 
the reliable detection of vaginal fluid in forensic laboratories.  Historically, Lugol’s 
staining of glycogenated epithelial cells of the vaginal wall was thought to provide an 
indication of the presence of vaginal fluid.  The iodine molecules in the Lugol’s stain fit 
26 
into the helical structures that make up the glycogen molecule forming a dark brown 
complex.  However, this is no longer considered to be specific for vaginal cells as it is 
difficult to differentiate vaginal and buccal epithelial cells with this stain [31].  
Glycogenated epithelial cells are also found in the lining of the anus, pharynx, esophagus, 
urethra and glans penis [3].  Additionally, the amount of glycogenated cells in the vagina 
varies with hormonal changes.  High levels of estrogen support higher concentrations of 
glycogenated cells, but these levels drop with menstruation, in pre-pubescent and post-
menopausal women. Fluctuations in the levels of glycogenated cells have also been 
observed during pregnancy and in association with the use of hormonal contraceptives.  
The Dane’s staining method has also been evaluated as a means of differentiating 
glycogenated epithelial cells originating from the vaginal versus the oral/buccal cavity.  
When applied, the Dane’s stain (a mixture of hemalum, phloxine, Alcian blue, and orange 
G) generally stains buccal cells orange/pink with red nuclei (although this showed
considerable variability within and between individuals) and stains vaginal cells bright 
orange with orange nuclei.  The Dane’s stain will also stain epithelial cells from skin (cells 
which often lack nuclei) red and orange [3].  While pure samples of vaginal, epithelial, and 
buccal cells can be readily differentiated with the Dane’s stain, mixtures of these cell types 
could not be reliably distinguished. As a result, this histological staining approach has 
limited applicability when working with forensic samples.  
During menstruation, blood and the degenerated lining of the endometrium from 
the uterus are sloughed off and eliminated from the body.  Blood loss is controlled through 
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a balance of blood coagulation and clot dissolution that allows for removal of tissue 
fragments from the uterus.  During clot dissolution, cross-linked fibrin is cleaved by the 
enzyme plasmin, producing a degradation product, D-dimer, in the process.  An ELISA 
assay can be used to detect the D-dimer.  Additionally, Seratec PMB is a recently developed 
immunochromatographic multiplex assay that allows for the simultaneous detection of 
human hemoglobin and D-dimer for the differentiation between peripheral blood and 
menstrual fluid [32].  While D-dimer is present in peripheral blood, it is found at much 
lower concentrations which are generally below the detection limits of these assays.  
However, postmortem blood contains higher levels of D-dimer and thus can produce a 
positive result in the absence of menstrual blood. 
Historically, lactate dehydrogenase (LDH) detection was also used for the forensic 
identification of menstrual fluid.  LDH plays a major role in glycolysis.  Five LDH 
isoenzymes can be found in blood, each composed of four subunits with various 
combinations of subunit A and subunit B.  For example, LDH1 is composed of four 
identical B subunits while LDH5 is composed of four identical A subunits (Figure 15).  
Each of the five isoforms can be differentiated based on differences in mobility using 
electrophoresis [33].  Typically, LDH1, LDH2 and LDH3 are predominantly observed in 
peripheral blood while LDH4 and LDH5 are predominantly observed in menstrual fluid.  
As LDH levels can fluctuate and can be found in other tissues, the forensic utility of this 
test for menstrual fluid is considered to be limited at best [34].  
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Figure 15:  Five isoforms of lactate dehydrogenase (LDH) found in blood.  Each isoenzyme 
is composed of four subunits. Isoenzymes differ from one another based on the specific 
combinations of the A and B subunits.   
1.2  Future Serological Techniques 
Given the substantial limitations associated with current serological techniques, 
several novel approaches to identifying biological fluids have been explored in recent 
years.  These include the use of epigenetic modifications, messenger RNA markers, micro 
RNA expression patterns, and high-specificity protein biomarkers.  Of these, epigenetics 
has also been used in an effort to predict age signatures from biological fluids.  All of these 
emerging techniques aim to improve the sensitivity and specificity of forensic body fluid 
identification while allowing for rapid sample analysis and easy adoption by analysts in a 
case-working environment.  
1.2.1  DNA Methylation Assays for Body Fluid Identification 
Epigenetics is the study of potentially transmissible modifications to DNA that are 
typically associated with changes in DNA methylation that leads to changes in gene 
expression.  Methylation of cytosine residues, typically located at CpG islands in promoter 
regions upstream of genes, enable gene silencing [35].  Conversely, unmethylated/ 
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undermethylated promotor regions of genes allow for the transcription of genetic 
information.  Methyltransferase is responsible for in vivo cytosine methylation by 
transferring a methyl group from S-adenosylmethionine to cytosine at the carbon-5 
position.  Tissue-specific patterns of DNA methylation have shown promise as a means of 
body fluid identification.  
This technique relies on detecting these tissue-associated differences in methylation 
pattern. For example, several regions have been found that are consistently 
hypomethylated in cells from seminal fluid as compared to other biological fluids.  
Typically, bisulphate conversion is used to convert un-methylated cytosine residues to 
uracil via hydrolytic deamination (Figure 16).  Methylated cytosine residue specific PCR 
primers can then be used to amplify targeted regions of interest.  Alternatively, methylation 
specific restriction enzymes can be used to cleave DNA at unmethylated sites, leaving 
methylated DNA intact.  The polymerase chain reaction can then be used to amplify intact, 
methylated  DNA  while  the  cleaved,   unmethylated  regions  are  not  copied.   Another 
technique for isolating methylated DNA is methyl-DNA immunoprecipitation.  
Antimethylcytosine antibodies are used to bind methylated cytosines on sheared DNA 
which can then be isolated via immunoprecipitation.  
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Figure 16:  Bisulphate conversion of 5-methylcytosine.  
Blood (based on the FOX03 and EFS genes) [36], saliva (based on the SLC12A8 
and BCAS4 genes), semen (based on the DACT1 and C12orf12 genes) [37] and skin cells 
have all been successfully identified using methylation-based tissue identification [35].  
More recently, tissue specific differentially methylated regions have also been identified 
for vaginal secretions (based on the LOC404266 and HOXD9 genes) and menstrual fluid 
(based on the LC26A10 and LTBP3 genes), allowing for its differentiation from peripheral 
blood [32].  Positive results have also been generated for casework-type samples for semen 
and bloodstains that had been aged for up to 20 months.  A commercial assay for the 
detection of seminal fluid, Nucleix DSI-Semen kit, has been developed and validated [38, 
39].  Multiplex testing has recently been published but not yet commercialized [40, 41].  
A potential advantage of this assay is that it can easily be incorporated into the 
existing DNA workflow for most operational forensic laboratories.  Additionally, the 
multiplexed analysis of different body fluids in one assay is possible and would eliminate 
the need for multiple separate tests to be performed on the same sample for each biological 
fluid of interest.  This would save time and sample as well as eliminate the need for analysts 
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to be trained and to stay proficient in multiple analytical techniques.  Further research, 
however, is still needed in order to assess how methylation patterns change in response to 
certain factors such as environmental stimuli, aging and disease as well as to evaluate the 
degree of inter-individual epigenetic variation [42] that exists with human populations. 
While epigenetic modifications associated with DNA from seminal fluid has been 
shown to be robust and reliable, the pattern of varying degrees of methylation in other 
bodily fluids makes interpretation of results, especially in mixed fluid samples, complex.  
Furthermore, while techniques such as DNA methylation microarrays and genome bisulfite 
sequencing allow for the detection of enough multiplexed targets to be forensically 
informative, these approached require large quantities of high-quality DNA.  This may not 
be feasible for many forensic samples that are often present only in trace amounts or have 
been subjected to environmental degradation.  Alternative techniques such as methylation 
quantitative PCR and bisulphate pyrosequencing are more amenable for lower 
quality/quantity input but these approaches are more limited in terms of their multiplexing 
capabilities [43, 44].  
As mentioned previously, methylation patterns have been found to be susceptible 
to change due to the natural aging process. To detect methylation, targeted bisulfite 
conversion detected with a SNaPshot assay or pyrosequencing has been the method of 
choice.  The bisulfite conversion deaminates non-methylated cytosine and converts it to 
uracil (PCR amplification converts this to thymine) while methylated cytosine is 
unaffected.  The SNaPshot assay can be used to detect single base differences by 
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incorporation of terminating dideoxynucleotide triphosphate bases.  Extension products 
can then be analyzed using capillary electrophoresis (Figure 17).  The percent of 
methylation can then be estimated by dividing C/G intensity (unconverted methylated 
DNA) by C/G plus T/A (bisulfite converted unmethylated DNA) intensities.  Review of 
online databases of genome-wide methylation profiling (most commonly from Illumina’s 
Human Methylation Bead Chip technology) has been used to identify candidate target 
methylation sites [45].  
To build age prediction models, samples of a particular biological fluid are 
collected from individuals spanning gender, ethnicities and chronological age.  
Multivariate linear regression coefficients and significance of correlation between 
chronological age and DNA methylation ratios can then be used to identify promising 
targets for age prediction [45].  These accumulated methylation changes associated with 
age may be tissue specific.  Studies have demonstrated that different sites are better 
correlated with age in specific tissues.  Therefore, multiple sites within a specific tissue 
which correlate with the aging process for that particular tissue type will need to be 
identified.  
For example, in one study methylation of a CpG site, PRMT2, showed no 
correlation with age in saliva or semen samples.  However, this epigenetic marker was 
found to be age associated in blood samples [35].  In another study, two epigenetic markers 
in the TTC7B gene and one additional epigenetic marker in the NOX4 gene showed a high 
correlation between predicted and chronological age in semen samples [45].  An additional 
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six age-associated CpG markers on the SST, CNGA3, KLF14, TSSK6, TBR1 and SLC12A5 
genes have been identified in saliva [46].  Multiple other markers have been identified in 
blood samples from individuals of varying age and ethnicity that correlate to age prediction 
– typically with an estimate of error of between 3 to 6 years [47].
While this work looks promising, the identification and application of DNA 
specific methylation patterns as a predictive tool for age estimation is still in the early stage 
of development.  Additional areas of research have been focusing on combining epigenetic 
analysis and next generation sequencing approaches for body fluid identification. It is 
thought that this may provide additional supporting evidence for predictive age signature 
applications [48].  
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Figure 17:  Illustration of bisulfite sequencing of cytosine methylation where unmethylated 
cytosine is converted to uracil.  PCR and sequencing then ultimately convert cytosine to 
thymine; thereby indicating the site was unmethylated.  
1.2.2  RNA Based Assays for Body Fluid Identification 
Messenger ribonucleic acid (mRNA) is the product of transcription that conveys 
genetic information from DNA to the ribosome for translation where it specifies the amino 
acid sequences of the protein products of gene expression.  Just as tissue specific 
differentially methylated regions of DNA were identified for the epigenetic identification 
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of biological fluids, tissue specific gene expression has been targeted for mRNA-based 
assays.  These assays seek to detect mRNA transcripts that are exclusive to certain cell and 
tissue types.  
A major advantage to mRNA body fluid analysis is that it uses standard techniques 
and instrumentation already widely implemented in forensic biology laboratories.  The two 
most common techniques used for mRNA body fluid analysis are reverse transcription 
followed by end-point PCR and capillary electrophoresis as well as reverse transcription 
coupled with quantitative PCR (qPCR).  During reverse transcription, a complementary 
DNA (cDNA) is produced from an mRNA template by reverse transcriptase.  Primers for 
established body fluid-specific gene transcripts are incorporated during a multiplex or 
several singleplex PCR reaction(s) and the resulting amplicons are analyzed via capillary 
electrophoresis.  The expression of multiple mRNA markers is used to deduce the 
biological source of a particular sample [49].  Alternatively, cDNA can be amplified via 
quantitative PCR.  During qPCR, pre-designed target-specific primers and TaqMan (or 
similar) probes can be used to quantify gene expression [50-52].  Reverse transcription 
coupled with end-point PCR and capillary electrophoresis or qPCR are sensitive techniques 
for quantifying mRNA expression in samples, however, the degree of multiplexing is 
limited. As a result, only a few mRNA biomarkers can be assayed in a single reaction. 
To identify novel body fluid specific markers and better understand the gene 
expression variation between forensically relevant body fluids, whole transcriptome 
analysis was needed.  DNA microarrays has been useful in these discovery projects.  In 
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one approach, oligonucleotide probes are attached to or synthesized on the solid surface of 
a chip. These are then hybridized to cDNA or RNA strands of interest.  Fluorophores can 
be used to detect probe-target hybridization events [53, 54].  Subsequent analyses of gene-
expression profiles in populations of study subjects have identified multiple tissue-specific 
mRNA markers for those body fluids most frequently encountered in forensics.  
For example, HBA1 (alpha 1 hemoglobin), HBB (beta hemoglobin), SPTB (beta 
spectrin) and PBGD (porphobilinogen deaminase) are a few of the mRNA markers 
reported to be “specific” to peripheral blood.  Similarly, HTN3 (histatin 3), MUC7 (mucin 
7) and STATH (statherin) are mRNA markers reported to be “specific” to saliva.  The
KLK3 (prostate-specific antigen), PRM1&2 (protamines 1 & 2), and SMG1 (semenogelin 
1) transcripts have been proposed as specific mRNA markers for seminal fluid; HBD1
(beta defensin 1) and MUC4 (mucin 4) transcripts have been proposed as -“specific” 
markers for vaginal secretions; and the MMP7 and 11 (matrix metalloproteinase 7 and 11) 
transcripts have been proposed as “specific” markers menstrual fluid.  A large number of 
studies in the published literature have assessed the potential utility of these mRNA 
markers [50, 55-59]. In addition to the tissue-specific gene transcripts used for body fluid 
identification, a number of consistently expressed housekeeping genes have also been 
proposed for use as internal controls [52].  Recently, a commercial product, ParaDNA® 
Body Fluid ID System, has been developed.  This portable device targets mRNA markers 
for seminal fluid, sperm cells, vaginal fluid, saliva, blood and menstrual fluid [60].   
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While these assays and commercially available tests are more specific than current 
testing methodologies, they suffer from the general stability limitations of any work 
involving mRNA targets.  Degradation due to endogenous ribonucleases frequently effect 
mRNA stability in biological samples.  Additionally, crime scene samples are often 
exposed to ultraviolet light, moisture and wide temperature ranges – all of which can lead 
to mRNA degradation in biological fluid samples.  However, body fluids have been 
successfully detected using mRNA markers in aged samples that have been maintained 
under appropriate storage conditions.  
In an effort to address the stability concerns associated with larger mRNA 
transcripts, microRNAs have been evaluated as an alternative type of RNA biomarker. 
MicroRNAs, which regulate gene expression, are much smaller and more abundant than 
mRNAs. While this makes them more stable targets, the expression of microRNAs is more 
ubiquitous.  Thus, although broad expression patterns characteristic for forensically 
relevant fluids can be identified, the interpretation of body fluid mixtures continues to 
poses a formidable challenge [61, 62].   
1.2.3  Proteomic Based Assays for Body Fluid Identification 
A particularly promising approach for the serological identification of biological 
fluids combines high-specificity protein biomarkers with mass spectrometry. This allows 
for the direct identification of target proteins (even in partially degraded samples); true 
confirmatory identification and greatly enhanced sensitivity. 
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A proteome is the full complement of proteins present in an organism while 
proteomics is the study of these expressed proteins.  Protein biomarkers have attracted 
significant interest in recent years due in large part to the strides that have been made in 
the tools available to identify and characterize them.  It is now possible to rigorously map 
entire proteomes with high reproducibility. Techniques such as differential 2-D gel 
electrophoresis or multidimensional protein identification technology (MudPIT) [63, 64] 
have made it possible to identify a vast number of candidate protein biomarkers [65-68].  
Once potentially useful candidate protein biomarkers have been identified, mass-
spectrometry-based targeted-ion assays can facilitate the unambiguous detection and 
quantitation of even low abundance biomarker protein targets against a background of 
other non-target molecules in complex biological matrices [63, 69, 70].  
This has resulted in a wealth of new opportunities to develop protein-based assays 
for both medical and forensic applications.  Most forensic approaches for stain 
identification follow a “bottom-up” shotgun approach to biomarker detection and 
identification. In this approach, a complex biological sample is first enzymatically cleaved 
and small peptides (~15 amino acids in length) are the fractionated by liquid 
chromatography followed by identification of protein targets of interest using tandem mass 
spectrometry [71].  
One of the significant advantages of a protein biomarker approach is the diversity 
of potential targets that are made possible due to post-translational modification in different 
tissues. Another key advantage is the stability of many proteins under conditions that lead 
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to degradation of other biological macromolecules. Proteins are among the most long-
lasting of all biological molecules having been routinely isolated from even ancient 
biological material [72] and post-mortem tissue [73].  Even when degradation begins to 
occur, simple modification of detection methodologies focusing on the detection of 
fragmented proteins still allows for reliable detection.  
1.3  Research Objectives 
This dissertation research was designed to develop and assess the potential utility 
of a targeted-ion Triple Quadrupole Mass Spectrometry in Multiple Reaction Monitoring 
mode (QQQ-MRM) approach for the identification of biomarker targets specific to 
forensically relevant biological fluids.  The application of this technology, especially for 
the front-end processing of sexual assault evidence, has been a central focus of this 
research. To achieve this, selected biomarkers from previous studies were incorporated into 
a multiplex QQQ-MRM method for the simultaneous detection of up to six biological 
fluids. The subsequent developmental validation of this QQQ-MRM assay provided 
forensic analysts with a high level of confidence in the accuracy of the results obtained. 
This multiplex assay was then used as a foundation for the development and 
optimization of a monoplex QQQ-MRM assay for semen, with the goal of using this for 
the high-throughput analysis of sexual assault samples. This was achieved by eliminating 
from the larger multiplex assay all biomarker peptides not specific to semen. Doing so 
maximized the dwell time efficiency of the instrument; thereby increasing the assay’s 
detection sensitivity for seminal fluid targets. Assay specificity was assessed by analyzing 
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a series of mixtures consisting of saliva, semen, vaginal secretions, urine, peripheral and 
menstrual fluid. The extent to which the optimized monoplex QQQ-MRM assay for semen 
can extend the post-coital interval for the detection of seminal fluid in cervico-vaginal 
samples was then assessed relative to the results obtained with the 
immunochromatographic assays currently employed by forensic laboratories. 
The qualitative monoplex assay for seminal fluid detection was then further 
modified to develop an absolute quantitation QQQ-MRM assay for seminal fluid. By 
establishing the limit of detection (LOD) and quantitation (LOQ) for the assay, the 
relationship between quantitative levels of target seminal fluid peptides and the ability to 
generate male-targeted Y-chromosome short tandem repeat (Y-STR) haplotypes from 
vaginal swabs collected at various post-coital intervals was assessed. The quantitative 
monoplex assay was also used to estimate of the rate of authentic false positive results 
associated with immunochromatographic assays that target the same proteins quantitated 
by the QQQ-MRM method. The successful completion of these objectives has important 
implications for the successful prosecution of the perpetrators of sexual assault as well as 
the effective defense of those who are wrongly accused.  
1.4  Hypotheses 
The overarching hypothesis that was tested in the course of this dissertation 
research is that a targeted-ion mass spectrometry based proteomic assay would provide for 
the sensitive and specific identification of biological fluid specific protein targets 
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(especially as compared to currently employed immunochromatographic based serological 
assays).  The specific hypotheses that were at the core this research therefore are: 
1. The use of a mass-spectrometry based assay for seminal fluid will surpass the
sensitivity levels of the antibody-based assays employed by most forensic 
laboratories. 
2. The accuracy, reliability and enhanced sensitivity of the proposed assay will extend
the post-coital interval during which it is reasonable to collect sexual assault 
samples that are likely to yield useful results.  
3. A quantitative mass-spectrometry based seminal fluid assay will make it possible
to assess the likelihood of obtaining a useful Y-STR haplotype based on the 
quantity of seminal fluid biomarkers present on the post-coital swab (i.e., the ability 
to use protein quantities in the same way as DNA quantitation data is currently used 
to screen samples for downstream DNA profiling).  
4. The accuracy and enhanced sensitivity of a QQQ-MRM assay for semen proteins
can be used to independently assess the rate of actual false positive results (i.e., 
non-specific binding events) associated with the antibody-based lateral flow tests. 
1.5 Dissertation Structure 
Within each chapter of this dissertation an introduction will establish the necessary 
background content and justification for the given set of experiments.  A description of the 
experimental methods will be provided and a summary of all pertinent results will be 
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detailed. Each chapter discusses the significant research findings that were made including 
any caveats relevant to adoption by forensic practitioners in an operational environment.  
Chapter 2 focuses on highlighting one of the inherent limitations associated with 
the most commonly employed serological method in forensic laboratories.  Namely, this is 
the well-documented lack of specificity that has been encountered with the use of 
immunochromatographic assays.  Chapter 3 focuses on the developmental validation of an 
MRM method for the concurrent identification of six biological fluids of forensic interest.  
Chapter 4 assesses the feasibility of a mass spectrometry-based body fluid assay for the 
analysis of sexual assault samples by narrowing the scope of the assay to seminal fluid in 
order to maximize assay sensitivity.  Chapter 5 focuses on how a quantitative (versus 
qualitative) method for seminal fluid detection can be used to establish true false positive 
rates for common immunochromatographic assays that target prostate specific antigen and 
semenogelin proteins. Chapter 5 also focuses on the use of semen protein quantitation by 
mass spectrometry for the reliable prioritization of samples for downstream genetic testing. 
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CHAPTER 2: FALSE POSITIVE IMMUNOCHROMATOGRAPHIC TEST 
RESULTS ASSOCIATED WITH ORGANIC ACIDS 
2. Introduction
The ability to detect biological fluids recovered from a crime scene can provide 
useful information for the investigation of a crime.   Specifically, this information may be 
used to prioritize testing of items of evidence, direct downstream testing methodologies for 
the development of genetic profiles, or to provide investigators contextual information 
paramount to the criminal investigation.  In some instances, being able to detect a 
biological fluid on an evidentiary sample, even in the absence of genetic analysis, may be 
sufficient to influence the outcome of an investigation and in some instances a court case.  
It is therefore critical for forensic practitioners to be able to provide information on the 
detection (or lack thereof) of a biological fluid as well as to be aware of the limitations 
associated with the applied methodology.  It is for this reason, that an increased emphasis 
has been placed on developing serological tests that optimize sensitivity and specificity 
while minimizing sample processing time so as to reduce the potential for backlogs in the 
testing of crime scene evidence.  One of the most common serological methods employed 
currently in crime laboratories for the identification of biological fluids is the use of 
immunochromatographic assays. 
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Laminar flow immunochromatographic assays are commercially available from 
multiple manufacturers and are commonly used in forensic practice to detect the presence 
of bodily fluids including, blood, semen, saliva, and urine [1, 7, 26, 74-85].  These assays 
employ labeled antibodies specific to a protein or other small molecular target considered 
to be characteristic of (but not necessarily unique to) a given bodily fluid.  When an extract 
of a test sample is introduced to the sample well, the target antigen forms a complex with 
mobile phase antibodies that are typically conjugated to colloidal gold particles. The 
antigen-antibody complexes that form migrate down a lateral flow membrane.   
Immobilized at a test site on the membrane are additional antibodies for different epitopes 
on the same target protein that bind the complex forming an antibody-antigen-antibody 
sandwich. Accumulation of the labeled antibodies from the sample well at the test zone 
facilitates visual detection of target antigen.  Labeled antibodies not captured at the test 
zone continue to migrate to a control zone where they are captured by immobilized anti-
immunoglobulin antibodies to form another visible line.  This second visible line indicates 
the test performed as designed.  Sometimes, depending on manufacturer, an additional 
control line is added making it possible to estimate the quantity of target protein in a 
sample.  While immunochromatographic assays represent a sensitive and efficient method 
for forensic serological testing, the limitations associated with these assays must be fully 
understood so as not to mislead investigators or the trier of fact.  
Given their reliance on antibody binding reactions, these assays suffer from similar 
types of limitations regardless of manufacturer.  Depending upon the body fluid specificity 
of the proteins used for any particular assay, there may be other non-target biological fluids 
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that contain equal or lower concentrations of the target biomarker that are still capable of 
producing positive reactions [7, 14, 15, 18, 26, 73, 86].   Additionally, while not as well 
documented in the literature, chemically induced non-specific protein aggregation as well 
as cross-reaction to structurally similar non-target antigens can both lead to false positive 
reactions [18, 87].  One product’s user manual highlights the potential for non-specific 
binding events  by suggesting test results may be influenced by acidic  pH in combination 
with the presence of organic acids [88].  This study aimed to evaluate how pH and the 
presence of organic acids may influence false positive results of multiple 
immunochromatographic assays designed to target blood, semen, saliva and urine. 
Immunochromatographic assays from multiple different manufacturers were 
evaluated. Specifically, the ABAcard® p30 and ABAcard® HemaTrace® (Abacus 
Diagnostics®); RSID™-Urine, RSID™-Semen, RSID™-Blood, and RSID™-Saliva 
(Independent Forensics); and PSA Semiquant, HemDirect, and Amylase Test (Seratec®) 
were evaluated.  Citric acid and lactic acid were selected based on widespread use of these 
organic acids in commercial products. Sample pH was adjusted to determine the degree of 
pH dependence of false positive results with organic acids.  Manufacturer-specific buffers 
were utilized to evaluate their efficiency in mitigating false positive results. Common 
household and commercial products that contain organic acids were also analyzed.  
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2.1 Methods 
2.1.1 Chemicals and Reagents 
Citric acid (anhydrous) and lactic acid (85% pure) were obtained from Sigma 
Aldrich (Allentown, PA).  Hydrochloric acid (HCl) (36.5-38%) and 10N sodium hydroxide 
(NaOH) were purchased from BDH Analytical Chemicals (Poole, United Kingdom).   
Deionized water was obtained in house.  All pH measurements were made using a Mettler 
Toledo FiveGo pH/mV meter (Washington Crossing, PA).  
RSID™-Saliva, RSID™-Semen, RSID™-Urine, and RSID™- Blood kits were 
purchased from Independent Forensics (Hillside, IL).   ABAcard® p30 and ABAcard® 
HemaTrace kits were purchased from Abacus Diagnostics (West Hills, CA).  SERATEC® 
PSA Semiquant, SERATEC® HemDirect Hemoglobin Test, and the SERATEC® Amylase 
Test kits were purchased from Seratec® (Goettingen, Germany). See Table 1 for more 
specific information pertaining to selected immunochromatographic assays evaluated in 
this study.  All reagents were stored according to manufacturer’s guidelines.  Household 
products and beverages that were evaluated for their potential to produce false positive 
results included 1% cow’s milk, orange juice, white wine, apple juice, Monster Energy 
drink, Windex®, Febreze, white vinegar, and Pine-Sol). These were purchased from local 
retail outlets or voluntarily donated by laboratory staff.  
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Table 1. Overview of Immunochromatographic Assays Evaluated. 
2.1.2 Solution Preparation 
A 0.3M citric acid solution was prepared by adding 5.76 grams of citric acid 
anhydrous to 100 mL of deionized water.   A serial dilution of the 0.3M citric acid stock 
solution was used to prepare the following series of two-fold dilutions:  0.15M, 0.075M, 
0.0375M, 0.0187M, and 0.0093M.  A 0.3M lactic acid solution was prepared using 2.62 
mL 85% pure lactic acid added to 97.38 mL of deionized water. All stock solutions were 
Manufacturer Test Target Antigen Dye 
Seratec® 
PSA Semi-quant Prostate Specific Antigen Colloidal Gold 
HemDirect Hemoglobin Colloidal Gold 




ABAcard® p30 Prostate Specific Antigen Possible Colloidal Gold, 
Colloidal Silver, 




Hemoglobin Possible Colloidal Gold, 
Colloidal Silver, 




RSID™-Semen Semenogelin Colloidal Gold 
RSID™-Blood Glycophorin A Colloidal Gold 
RSID™-Saliva Salivary Amylase Colloidal Gold 
RSID™-Urine Tamm Horsfall  
Glycoprotein (Uromodulin) 
Blue Latex Bead 
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adjusted to a pH of 2 to 12 while dilutions were adjusted to pH 4 using HCl and NaOH 
solutions.  Neat citric acid and lactic acid solutions were determined to have a pH of 1.74 
and 2.19, respectively. 
2.1.3  Citric Acid and Lactic Acid pH Series Studies 
The citric and lactic acid stock and dilutions were tested on all 
immunochromatographic assays which included RSID™ Saliva, RSID™ Semen, RSID™ 
Urine, and RSID™ Blood kits; ABAcard® p30 and ABAcard® HemaTrace kits; PSA 
Semiquant, HemDirect Hemoglobin Test, and the Amylase Test kits following the 
manufacturer’s recommendations.  Negative results on all assays were confirmed after 10 
minutes.  The dilutions that produced the last observable false positive result at both pH 
extremes were performed in triplicate.  
2.1.4  Deionized Water Study 
To determine the potential effect of pH separate from that of organic acids, 
deionized water was adjusted to a pH of 2 to 9.  The pH values that generated a false 
positive reaction with the citric acid stock solution (assay specific) and the acidified water 
(pH 2) were assessed across all immunochromatographic assays.   
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2.1.5 Kit-Specific Buffer Study 
The citric acid stock solution (pH 4) was diluted 1:1 in kit specific assay buffer.  
The resulting buffer-diluted organic acid solutions were then re-tested on the corresponding 
immunochromatographic assay. 
2.1.6  Common Beverages and Household Products 
Household products or beverages were purchased from retail outlets or voluntarily 
donated by laboratory staff.  All liquids were analyzed neat following individual 
manufacturer guidelines.  If a positive or invalid result was generated, the product was 
diluted 1:1 with kit specific buffer and then re-analyzed.  
2.2  Results 
2.2.1 Citric Acid and Lactic Acid pH Series 
The range of false positive results observed using the 0.3M citric acid stock solution 
varied both by assay and manufacturer (Table 2).   The Seratec® Amylase Test and RSID™ 
Urine assay generated false positive results over the widest pH range (between pH 1.74 – 
11 and pH 3 – 12 respectively).  For most other assays, solutions with extreme pH values 
(pH 2 and pH 12) consistently produced invalid results.  The ABAcard® HemaTrace® 
generated the fewest false positive results (i.e., only pH 4 produced a false positive result).  
Across all kits, the greatest frequency of false positive results was observed between pH 4 
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and pH 10.  Each test resulted in reproducible false positive responses when tested in 
triplicate. 
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Table 2. 0.3M Citric Acid Results for all Lateral Flow Assays Evaluated Over a pH Range 
of 1.74 to 12.   
Note:  Not tested (NT); Positive (+); Positive confirmed in triplicate (+++); Negative 
(NEG); Invalid (INV). 
The pH ranges that generated false positive results for each assay differed between 
citric and lactic acid (Table 3).  Despite having readily generated false positive results with 
citric acid solutions, neither the ABAcard® Hematrace® nor the SERATEC® HemDirect 
assays produced any false positive responses in the presence of lactic acid.  In contrast, the 
Independent Forensics assays produced generally concordant results with 0.3M lactic acid 
(pH 4 to 11) as compared to citric acid. The ABAcard® p30 and SERATEC® PSA 
Semiquant  assays produced false positive results with lactic acid only at acidic  pH values 
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(pH 2 to 4) despite producing false positive results at both acidic and basic pH values in 
the presence of citric acid.  False positive results demonstrated repeatability when testing 
was performed in triplicate.  
Table 3. 0.3M Lactic Acid Results for all Lateral Flow Assays Evaluated Over a pH Range 
of 2.19 to 12.   
Note:  Not tested (NT); Positive (+); Positive confirmed in triplicate (+++); Negative 
(NEG); Invalid (INV).     
2.2.2. Citric Acid Dilution Series 
A molarity of 0.3 was selected for the citric acid stock solution as this represents 
the most concentrated molarity found in natural products (citric juices).  A citric acid 
dilution series was also assessed for the potential to produce false positive results (Table 
4).  Both the ABAcard® p30 and RSID™ Urine produced false positive results across the 
entire dilution range evaluated.  All other assays, with the exception of the SERATEC® 
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HemDirect, produced false positive results down to a 0.0375M or 0.0187M solution.  Of 
particular note were the results obtained for the RSID™ Blood assay. Originally, this lateral 
flow test generated a negative result with the 0.3M citric acid stock solution.  However, 
when diluted, the citric acid then produced in false positive results down to a citric acid 
dilution of 0.0375M.  
Table 4.  0.3M Citric Acid Dilution Series Results for all Lateral Flow Assays Evaluated.  














ABAcard® p30 + + + + + +++ 
ABAcard® 
HemaTrace® 
















RSID™ Semen + + + +++ INV NT 
RSID™ Blood NEG + + +++ INV NT 
RSID™ Saliva + + + +++ INV NT 






PSA Semiquant + + + + +++ NEG 
HemDirect + + +++ NEG NT NT 
Amylase + + + + +++ NEG 
Note:  Not tested (NT); Positive (+); Positive confirmed in triplicate (+++); Negative 
(NEG); Invalid (INV).     
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2.2.3 Deionized Water Study and Kit-Specific Buffer Studies 
To assess the potential effect of pH in the absence of organic acids on non-specific 
binding events of lateral flow assays, pH adjusted water samples were also assayed.  
Acidified deionized water (pH 2) and median citric acid false positive pH values (kit 
specific) were tested.  No immunochromatographic assays produced false positive results 
for pH adjusted water in the absence of an organic acid (Table 5).  
The recommended best practice for testing liquid samples using immunochromato-
graphic assays is dilution of questioned samples with kit-specific buffered solutions and 
use of manufacturer-validated testing protocols.  In all instances, with the exception of the 
SERATEC® HemDirect and SERATEC® Amylase Test assays, dilution of the 0.3M citric 
acid solution (pH 4) with kit specific buffers was insufficient in mitigating false positive 
events (Table 5). 
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Table 5. Immunochromatographic Assay Results with Deionized Water at Various pH 
Values and with Kit Specific Buffer/Citric Acid Solutions.   
Assay 
Median H2O Result 
(pH of water) 
Acidified H2O 
Result 
(pH of water) 
Kit Specific Buffer 
Dilution Result  
(1:1 Dilution of    














ABAcard® p30 NEG (7) NEG (2) + 
ABAcard® 
HemaTrace® 
















RSID™ Semen NEG (7) INV (2) + 
RSID™ Blood NEG (9) INV (2) + 
RSID™ Saliva NEG (7) INV (2) + 








NEG (7) NEG (2) + 
HemDirect NEG (7) NEG (2) NEG 
Amylase NEG (7) NEG (2) NEG 
Note:  Deionized water at various pH levels in the absence of organic acids were tested on 
all immunochromatographic assays (first two results columns). Results with each assay for 
0.3M Citric Acid (pH 4) diluted 1:1 with kit specific buffer are illustrated in the third results 
column.  In all but two instances, the presence of kit specific buffer failed to mitigate false 
positive results due to non-specific binding events. Positive (+); Negative (NEG). 
2.2.4 Common Beverages and Household Products 
Common commercial products containing organic acids were selected for 
evaluation.  Neat liquid samples were assayed first.  In the event that a positive or invalid 
test result was observed, a 1:1 dilution with kit specific buffer was also tested.  All 
immunochromatographic assays were found to generate a false positive result with at least 
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one commercial product (Table 6).  Apple juice produced the most false positive results 
across all assays.  Neat white wine and white vinegar generated the highest rate of invalid 
test results. Dilution of these samples in kit specific buffer produced both negative and 
false positive results depending on the assay.  The ABAcard® HemaTrace® assay continued 
to produce the fewest false positive results, only generating a positive reaction with white 
wine and buffer diluted white vinegar.  In over half of all instances, dilution of commercial 
products with kit specific buffer failed to mitigate false positive results due to non-specific 

























































































































































A lack of specificity was observed for all immunochromatographic assays 
evaluated, regardless of target fluid or manufacturer.   Findings from this study suggest it 
is possible to obtain false positive results due to non-specific binding in the presence of 
organic acids over a wide pH range.  Therefore, the effects of organic acids do not appear 
to be strongly associated with pH as has been previously suggested.   Rather, these results 
may depend in some cases on the strength of the organic acid being tested (12).  Moreover, 
the addition of kit specific buffer often fails to negate these unwanted results.   While 
simple and sensitive, the possibility of false positive results due to non-specific binding 
within immunochromatographic cartridges should be taken into consideration when 
reporting results and conveying the potential significance of results to the trier of fact. 
Doing so should help to prevent overstatement of the strength of the results obtained with 
these assays (13, 26). 
Assay sample well antibodies are bound to microparticles (e.g, colloidal gold) 
through physical interactions involving non-covalent bonds which can be further 
strengthened through the use of chemical linkers (27, 28, 29, 30, 31).  The addition of an 
organic acid may disrupt these bonds resulting in microparticles with reactive sites.  As 
these microparticles migrate past immobilized antibodies on the lateral flow strip, it is 
reasonable to anticipate that these reactive sites could facilitate the aggregation of the 
microparticles in the absence of the target protein. Regardless of mechanism, however, it 
should  be  emphasized  that  the  findings  from  this  study  demonstrate  how  lateral flow 
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immunochromatographic tests can be greatly affected by non-targeted fluids, resulting in 
a false positive reaction that cannot be visually distinguished from that of a true positive 
result.  Therefore, these data underscore the presumptive nature of immunochromato-
graphic assays for forensic body fluid detection. 
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CHAPTER 3: DEVELOPMENTAL VALIDATION OF A MULTIPLEX 
PROTEOMIC ASSAY FOR THE IDENTIFICATION OF FORENSICALLY 
RELEVANT BIOLOGICAL FLUIDS 
3. Introduction
Current forensic methodologies for the identification of biological fluids still apply 
many of the same analytical techniques that have been used historically for a century or 
more; namely chemical reactions, color reactions produced as a result of enzymatic 
activity, immunological reactions, or, in the case of semen, direct visualization of 
spermatozoa by microscopy.  All of these techniques, however, suffer from not 
insignificant test-specific limitations.  Many of these tests are laborious, consumptive of 
evidentiary material (especially when multiple tests in series are required) and necessitate 
that analysts be proficient with a methodologically diverse range of laboratory techniques.  
In addition, most existing serological assays suffer from low selectivity, limited specificity 
and even when successful, produce only presumptive results, as highlighted in the previous 
chapter.   For some body fluids (e.g., vaginal fluid, menstrual fluid and nasal mucus), 
reliable serological assays do not currently exist – at least in the commercial space.  
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Due in large part to the limitations associated with existing methods of biological 
stain identification, several novel approaches to serological testing are being explored.  A 
preference for multiplex analysis that can simultaneously identify multiple body fluids 
without the need for additional testing has been a long-standing desire by the community 
of forensic practitioners. At the same time, the throughput demands faced by many forensic 
laboratories   necessitate   that  any  novel   procedures  for  body   fluid  identification   be 
compatible with current the protocols and overall workflow for DNA analysis.  The 
potential to bring greater standardization and automation to forensic serological testing is 
akin to the type of progress that has been achieved over the past few decades in DNA 
profiling.   
This chapter reports the development and validation of a targeted proteomic method 
for the simultaneous identification of forensically relevant biological fluids – namely 
peripheral blood, semen, saliva, urine and vaginal/menstrual fluid.  This method makes use 
of Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) in Multiple Reaction 
Monitoring (MRM) mode. This allows for the selective detection of a large number of 
peptides derived from body fluid-specific proteins [63, 89, 90].  
Previously, 2-dimensional HPLC has been used to identify candidate body fluid 
specific protein biomarkers. Following enzymatic cleavage, target peptides of specific 
amino acid sequences were selected for use in a target ion mass spectrometry.  In the 
present work, the most abundant and highly specific candidate peptide biomarkers for each 
biological fluid of interest were evaluated via LC-MS/MS analyses to confirm their body 
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fluid specificity in a sample population of at least fifty individuals.  Following analytical 
optimization and selection of product ion transitions for each target, a final multiplex MRM 
method was designed to simultaneously and unambiguously identify six biological fluids 
of interest.  This targeted ion assay underwent rigorous developmental validation and its 
forensic utility was demonstrated using simulated casework samples covering a wide 
variety of sample types consistent with those encountered in an operational forensic 
environment.  
3.1  Methods 
3.1.1  Chemicals and Reagents 
HemogloBind™ was purchased from Biotech Support Group. Ammonium 
Bicarbonate (ABC), Dithiothreitol (DTT), and Iodoacetamide (IAA), and 2,2,2-
Trifluoroethanol (TFE) were purchased from Sigma-Aldrich (St. Louis, MO).  Mass 
Spectrometry grade Trypsin Gold was sourced from Promega (Madison, WI). LCMS grade 
water, acetonitrile, methanol, and acetone were purchased from Honeywell/Burdick and 
Jackson (Muskegon, Michigan). All sample preparation was carried out in Eppendorf 
LoBind Proteion microcentrifuge tubes.  Absolute Quantification (AQUA) C-terminus 
labelled peptides were custom synthesized by New England Peptide (Gardner, MA) and 
delivered as lyophilized 2 nmol aliquots. Intact myelin basic and aprotinin stock solutions 
(1 mg/mL) were purchased from New England Peptide (Gardner, MA) for use as internal 
positive controls.  
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3.1.2 Body Fluid Collection 
Body fluids were collected in accordance with procedures approved by the 
University of Denver’s Institutional Review Board for Research Involving Human 
Subjects.  Peripheral blood was collected via venipuncture into blood tubes containing 
EDTA.  Semen and urine were both separately collected by having donors deposit fresh 
samples directly into sterile plastic specimen cups.  Saliva was obtained by having 
participants place Sarstedt Salivette™ saliva collection sponges into their mouths for 3-4 
minutes.  Sponges were then centrifuged for 2 min at 1500 RPM at 4°C to recover saliva.   
Semen-free vaginal secretions and menstrual fluid were collected from participants who 
had abstained from sexual contact for a minimum of 12 days.  Vaginal secretions were 
collected using a Softcup, which was placed in the vagina for a minimum of 1 hour then 
removed and the collected fluids placed into a sterile specimen cup.  The surface of the 
Softcup was irrigated with 1mL ultrapure water and transferred into a 15 mL conical for 
agitation by vortexing.  Menstrual fluid was collected using a DivaCup® which was placed 
in the vagina for a minimum of 1 hour during the first or second day of menstruation and 
then removed and placed into a sterile specimen cup.  The surface of the DivaCup® was 
irrigated with 1mL ultrapure water and the resulting fluids were transferred into a 15 mL 
conical for agitation by vortexing.  Following collection and processing, all samples were 
aliquoted into 1.5mL microcentrifuge tubes and stored at -80ºC.  In general, and unless 
otherwise indicated, 50 µl of blood or 125 µl of all other biological matrices were used for 
the proteomic identification of target proteins.  
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3.1.3 Casework-Type Samples 
The applicability of a mass-spectrometry based body fluid assay to samples 
encountered in a forensic context was assessed using a series of casework-type samples.   
Specifically, the ability of the biomarkers to be detected in body fluid samples recovered 
from a variety of substrates including cotton, denim, leather, metal, glass, plastic, sanitary 
napkins and Styrofoam™ were tested.   Similarly, the impact of exposure to environmental 
contaminants/insults was also assessed. For these assays, aliquots of bodily fluids applied 
to sterile cotton tipped applicators that had previously been dipped in such agents as 10% 
bleach, neat bleach, soil, detergent, spermicidal lubricants, chewing tobacco, and soda were 
used.   Swabs designed to simulate sexual assault type evidence were also assessed. These 
included oral swabs, rectal swabs, vaginal swabs, penile swabs and finger swabs. Finally, 
a series of aged body fluids stored at room temperature for a period of 2-7 years were 
analyzed. 
3.1.4  Protein Extraction, Quantification, and Digestion 
Dried stains were resolubilized by soaking in 400µL of diH2O for 30 minutes with 
frequent agitation by vortexing. This was designed to facilitate the separation of biological 
material from the substrate.  Sample substrates were then transferred into clean spin baskets 
and centrifuged at 14,000 RPM for 10 minutes.  Fluid samples were centrifuged at 14,000 
RPM for 10 minutes. If samples appeared to contain excessive quantities of hemolyzed red 
blood cells, 400 µL of HemogloBind™ was added to selectively remove cell-free 
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hemoglobin.  Samples were vortexed for 30 seconds and mixed via inversion for 15 
minutes prior to two centrifugation steps of 7,000 RPM for 2 minutes each.  For samples 
containing suspected denaturants (i.e., urea, detergents, etc.), precipitation using 1.2 mL of 
acetone was carried out.  Samples were vortexed, stored at -20 C for 30 minutes then 
centrifuged in a refrigerated microcentrifuge at 12,000 RPM for 10 minutes at 4C. An 
additional 600 µL of cold acetone was added to pelleted material and samples were stored 
at -20 C for 15 minutes prior to centrifugation at 12,000 RPM for 10 minutes in a 
refrigerated microcentrifuge at 4C. To resolubilize the pelleted protein, 150 µL of 50 mM 
ABC was added and samples which were placed in a thermomixer set at 30 C and 850 
RPM for 15 minutes.  Samples underwent a final centrifugation step in a refrigerated 
microcentrifuge at 4C at 12,000 RPM for 10 minutes. The resulting supernatant was then 
transferred to a clean 1.5mL microcentrifuge tube for analysis.  Following sample 
preparation protocols, total protein concentration was determined using a modified 
bicinchoninic acid assay (Micro BCA Protein Assay, Thermo Scientific Pierce) using 
bovine serum albumin as a known standard. 
Following protein quantification, 20 µg of total protein was transferred to a 1.5mL 
low retention microcentrifuge tube and lyophilized in a vacuum evaporator with the 
addition of 16 pmol bovine myelin basic and aprotinin internal digestion controls. Dried 
protein samples were reconstituted in 30 µL of denaturant buffer (50% TFE in 50 mM 
ABC with 5 mM DTT) and incubated at 60 C with shaking (850 RPM) for 1 hour. The 
resuspended proteins were then alkylated by the addition of 1.5 µL of 200 mM 
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Iodoacetamide (IAA) and shaken in the dark for 30 minutes at room temperature. 
Denaturant was diluted with 250 µL of 50 mM ABC and digested overnight at 37°C using 
trypsin at a 50:1 protein/enzyme mass ratio. Digested samples were then lyophilized in a 
vacuum evaporator and resuspended in 3% acetonitrile and 0.1% formic acid to a final 
concentration of 0.5 µg/µl.  Following digestion and purification, 10 µL labelled peptide 
master mix, consisting of 0.4 pmol/µl AQUA peptide stocks in 30% acetonitrile with 0.1% 
formic acid, were added to each sample.  
3.1.5  LC-MS/MS Analysis 
All samples were analyzed by LC-MS/MS on an Agilent Technologies HPLC-chip/MS 
system coupled to an Agilent 6430 Quadrupole Mass Spectrometer operating in positive 
dynamic Multiple Reaction Monitoring (dMRM) mode. Chromatographic separation was 
carried using a high capacity chip containing a 150mm 300 Å C18 analytical column with 
a 160 nL enrichment column. Columns were equilibrated in 0.1% formic acid in water. 
Run conditions employed “Buffer A” (0.1% formic acid in water) and “Buffer B” (90% 
acetonitrile, 10% water, 0.1% formic acid). An initial 30-minute run employed a gradient 
of 3% Buffer B to 35% Buffer B over 24 minutes. This was followed by 5 minutes at 90% 
Buffer B to flush the column and then reequilibration at 3% mobile phase A. A volume of 
sample containing 1 µg of total protein was injected with a flow rate of 400 nL/min.  This 
assay targets a total of 26 individual precursor ions consisting of 6 peripheral blood 
peptides, 5 saliva peptides, 6 seminal fluid peptides, 2 urine peptides and 7 
vaginal/menstrual fluid peptides.  Data were acquired through Mass Hunter software 
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(Agilent Technologies v.B.04.01).  Skyline software (v.3.1.0 MacCross Lab Software, 
University of Washington, USA) was used for the in silico selection of peptide transitions, 
optimization of collision energies as well as data analyses.  Target peptide detection was 
assessed as “positive” when all transition ions were detected at established ion and 
retention time ratios for “natural/native” and “heavy” labeled internal standards were met 
and peak morphology was of sufficient quality with a signal to noise ratio of at least 1:3.  
At least one peptide of a biological fluid must be unambiguously identified in order to 
positively identify the corresponding biological fluid.  
3.2  Results 
3.2.1  Confirmation of Body Fluid-Specific Targets 
This study leveraged a database of preexisting targeted-ion data generated using 
Quadrupole Time-of-Flight (QTOF) mass spectrometry. These data were generated in the 
course of previously published biomarker validation studies by the Danielson research 
group [90].  In an effort to ensure specificity, peptides and transitions were evaluated to 
identify those that had a unique fragmentation pattern, were abundant, efficiently ionized 
and had a mass to charge ratio greater than that of the tryptic peptide.  Peptides with 
interfering signals or those with a low response were eliminated from the list. Selection 
based on these criteria was intended to yield an assay that would be both specific and 
sensitive. A comprehensive list of target biomarker peptides and transitions for the 
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detection of each of six human body fluids (i.e., urine, semen, saliva, vaginal/menstrual 
fluid, and peripheral blood) is provided in Tables 7-11. 
Table 7. Urine Biomarker, Peptide and Transition List. 
Table 8. Seminal Fluid Biomarker, Peptide and Transition List. 
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Table 9. Saliva Biomarker, Peptide and Transition List. 
Table 10. Vaginal/Menstrual Fluid Biomarker, Peptide and Transition List.
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Table 11. Peripheral Blood Biomarker, Peptide and Transition List. 
3.2.2  Development of a Multiplex Proteomic Assay for Body Fluid Identification 
Optimized transitions for each target peptide as well as collision energy voltages 
were initiated with in silico predictions using the Skyline Proteomics Environment 
Software.  To confirm optimized transition selection, the in silico settings were compared 
to fragmentation spectra obtained experimentally through LC-MS/MS analysis of five 
single-source reference samples for each target body fluid.  Peak shape, abundance and 
retention time were monitored in order to confirm the unambiguous detection of each 
precursor-product ion pair. This information was used to evaluate the reliability with which 
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transitions were detected. Synthetic peptides were used for the optimization of collision 
energy  voltage  so  as to avoid any possible  matrix effects from  the  biological  fluids  of 
interest at this stage of the validation process.  Targeted-ion inclusion lists were compiled 
for each biological fluid.  Using saliva as an example, Figure 18 shows the total ion 
chromatogram (A) and the MRM TIC for the target semenogelin-II peptides (B).   
(A)
(B)
Figure 18:  (A)  Total ion chromatogram of a reference saliva sample with the percent 
organic phase used in the gradient overlaid in red.  (B)  MRM ion chromatogram of saliva 
with the percent organic phase used in the gradient overlaid in red.   
Biological fluids, analyzed in duplicate, were then compared to synthetic peptide 
reference standards to ensure consistency in ion ratios and retention time.  These measures 
were used to empirically verify that the assays actually identified the biomarker amino acid 
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sequences they were designed to detect.  While ion ratios were consistent between synthetic 
peptides and biological fluids, slight shifts in retention times were noted in a small number 
of samples. This phenomenon is not uncommon when working with nano flow systems.  
To normalize for this, internal reference standards purchased from New England Peptide 
(Gardner, MA) were used. These standards are synthesized with amino acid sequences that 
are identical to target biomarker sequences but with the incorporation of stable “heavy” 
isotope labels.   The stable isotope label behaves the same during HPLC separation but 
produces a mass shift, which allows the standard and natural peptide from a sample to be 
simultaneously monitored on the LC-MS/MS system (Figure 19). 
Figure 19:  Co-elution of an Absolute Quantitation (AQUA) peptide reference standard 
and a natural peptide generated from a sample digest.   
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Because forensic casework-type samples are typically of unknown composition 
and/or may contain environmental contaminants or other compounds with inhibitory 
properties that are co-extracted from evidentiary substrates, internal positive controls 
(IPCs) are often incorporated into forensic biological chemistries.  As it is reasonable to 
assume that forensic samples may also contain enzyme inhibitors that may adversely 
impact the efficiency of the proteolytic digestion of protein targets required for LC-MS/MS 
identification, an IPC consisting of a trypsin-cleavable protein was incorporated into this 
assay.  Ideal IPC candidates have highly specific peptide sequences and would not likely 
be found in casework-type samples.  Ultimately, bovine myelin basic protein from bovine 
brain was selected as an appropriate IPC.  This globular protein was added to samples and 
digested with trypsin alongside target proteins from biological fluids of interest.  The 
selected digest target (DTGILDSLGR) was evaluated in silico against the UniProt/Swiss-
Prot database to ensure that the sequences did not match any biomarker of interest as well 
as any other protein sequence found in humans.  The ratio between cleavage products 
resulting from sample digestion and that of a non-radioactive “heavy” carbon isotope 
labeled peptide of the same sequence was monitored during sample injections.  
MRM is the ideal protein analysis detection mode because the mass spectrometer 
is able to handle a large number of transitions per run without compromising sensitivity. A 
single MRM method capable of simultaneously detecting all biological fluids was 
developed after optimization and assessment of individual MRM methods for each fluid of 
interest. The final multiplexed MRM assay included a total of 26 peptides and 88 
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transitions. A comprehensive list of all selected peptide sequences, the m/z of their 
precursor and product ions and optimized collision energies can be found in Appendix I.  
3.2.3  Multiplex Validation 
A series of developmental validation studies were conducted based on multiple 
forensic community guidelines as applicable including the 2012 Scientific Working Group 
on DNA Analysis Methods (SWGDAM) Validation Guidelines for DNA Analysis 
Methods. These were designed to meet Standard 8.2 of the FBI’s “Quality Assurance 
Standards for Forensic DNA Testing Laboratories”.  While these guidelines were 
developed for the validation of DNA and RNA associated methods, they are in large part 
applicable to the validation of novel target ion mass-spectrometry methods for serological 
analyses.  In addition, the 2013 Scientific Working Group for Forensic Toxicology 
(SWGTOX) Standard Practices for Method Validation in Forensic Toxicology were also 
consulted and applicable guidelines followed to facilitate the design of a rigorous set of 
validation studies. 
3.2.3.1 Carry Over Study 
The reliability of the developmental validation studies requires clean injections of 
each sample such that the components of one injection do not interfere with subsequent 
injections.  In order to assess run-to-run carryover, proteins were extracted from neat body 
fluids with the most abundant and hydrophobic markers (i.e., hemoglobin beta found in 
peripheral blood and amylase found in saliva, respectively). These were injected at 
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maximum column capacity (i.e., up to 1μg of total protein). Each “maximum protein” assay 
was followed by a series of blank injections consisting of 3% acetonitrile, 0.1% formic acid 
to monitor for sample carry over.  No sample carryover was observed with blood digests 
at the maximum loading capacity of the column (1μg). However, carryover of amylase in 
saliva, which is both abundant and hydrophobic, was detected in the blank that followed 
injection of 1μg of saliva digest (Figure 20). Carryover was not detected in the subsequent 
injection (i.e., the second blank sample).  Based on these results, a blank sample was 
interspersed between all test samples for the remainder of the validation studies.  
Figure 20:  (TOP)  Amylase peptide marker LSGLLDLALGK with 1ng saliva on column. 
Note that the y-axis scale is in units of 105. (BOTTOM) Detection of trace amylase peptide 
marker LSGLLDLALGK carryover in a subsequent blank injection on the LC-QQQ.  Note 
that the y-axis scale is in units of 102. 
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3.2.3.2 Stability 
Stability studies assessed the stability of targets and standards over extended time 
periods on the instrument autosampler at room temperature (approximately 20 ºC).  Pooled 
samples from 10 donors were created for each biological fluid of interest.  Samples 
prepared  in  triplicate  were  analyzed  for  autosampler  stability at time 0.   These samples 
were then left on the autosampler and reinjected for an additional 3 days.  All peptide 
targets for all proteins of interest demonstrated autosampler stability up to 3 days as 
assessed on the basis of peak height intensity (Figure 21).  
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Figure 21:  Autosampler stability data as measured by peak area of target peptides as a 
function of days on autosampler.  Two of the least abundant peptides based on sensitivity 
studies are show for illustrative purposes.  Note the apparent increase in peptide peak area 
is most likely attributable to the progressive evaporation of the samples occurring over the 
3-day period.   
3.2.3.3  Sensitivity 
Sensitivity studies were carried out to determine the range of body fluid quantities 
that produced reliable results. For these studies, pooled samples from 10 human subjects 
were diluted with 50 mM ABC. A series of 2-fold dilutions ranging from 1:1 to 1:262,144 
were prepared in triplicate for each fluid.  Results from these sensitivity studies are 
presented in Table 12.  The limits of detection for each target biological fluid varied in that 
78 
peripheral blood peptide targets were the most sensitive (detection limit 1:262,144 or 
0.0001μL of target fluid for hemoglobin), the urine peptide targets were least sensitive 
(detection limit 1:128 or 0.3906μL of target fluid for uromodulin), and other fluids were of 
intermediate sensitivity; semen (detection limit 1:16,384 or 0.0031μL of target fluid for 
semenogelin II), saliva (detection limit 1:2,048 or 0.0244μL of target fluid for amylase), 
and vaginal fluid (detection limit 1:1,024 or 0.0488μL of target fluid for cornulin).  
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Table 12:  Sensitivity Limits for Individual Biological Matrices.  
Note:  Peptides that were identified in the majority of prep replicates are shown in dark green.  Red indicates where a paired 
peptide for a target protein dropped out prior to the secondary peptide target for the protein.  White indicates the failure to detect 
a given peptide in the majority or all of prep replicates.   
1               2               4               8               16             32             64             128          256          512          1,024       2,048       4,096       8,192       16,384       32,768       65,536       131,072       262,144       
















































3.2.3.4  Repeatability and Reproducibility 
To assess repeatability and reproducibility, equal-volume samples of a single body 
fluid from 10 human subjects were pooled.  From these stocks, a total of 18 replicates for 
each fluid were prepared such that two separate analysts could extract and analyze three 
samples from each fluid per day over a period of three days.  Sample extraction 
repeatability and reproducibility was assessed by evaluating the variation in calculated 
average BCA protein quantitative values.  The calculated percent coefficient of variation 
(%CV) values for each body fluid are indicated in Tables 13-18.  All targets fell within the 
maximum allowable %CV of 25%, which is a common industry benchmark for extraction 
repeatability and reproducibility. The only  exception to this was associated with the urine 
targets where greater sample-to-sample variation was expected here to the additional 
precipitation step that was included in the sample preparation protocol to reduce the 
negative impact of urea on the samples assay.  
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Table 13. Extraction Reproducibility for             
Peripheral Blood 
Table 14. Extraction Reproducibility for 
Urine (Precipitated)
Table 15. Extraction Reproducibility for 
Saliva 
Table 16. Extraction Reproducibility for 
Seminal Fluid 
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Table 17. Extraction Reproducibility 
for Vaginal Fluid 
Table 18. Extraction Reproducibility for 
Menstrual Fluid 
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The %CV values for each body fluid for the overall analytical method was assessed 
by evaluating the variation in normalized peak area (response ratio of tryptic peptide 
compared to labeled internal standard) and retention times (Table 19).  As was observed 
with the measured repeatability and reproducibility of the extraction protocol, the majority 
of overall analytical method repeatability and reproducibility were within maximum 
allowable ranges, with the notable exception of urine.   Elevated peak area %CV values for 
hemoglobin peptides (SAVTALWGK and GTFATLSELHCDK) and semenogelin-II 
peptide (DIFTTQDELLVYNK) were present in high abundance leading to suboptimal 
peak morphology and integration with high protein input samples. As a result, greater 
%CVs were observed for the area ratios of “natural” and “heavy” labeled peptides. This 
was readily ameliorated through sample dilution.  Conversely, the ALDGINSGITHAGR 
peptide for suprabasin exhibited elevated peak area %CV values for natural ion response 
ratios as this peptide was present at low quantities which approached the lower limit of 
detection.  The difficulty of detection at the lower limit of the assay unavoidably leads to 
greater %CV as it does with any other analytical assays.  
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Table 19.  Repeatability (Analyst 1 and 2) and Reproducibility (Overall) of the Analytical 
Method 
3.2.3.5  Species Specificity 
Both in silico and empirical methods were used to assess assay species specificity.  
The amino acid sequences of all target peptides were screened against the SWISS-PROT 
database containing 550,116 district proteins from 13,257 species.  Additionally, 
Analyst 1 Analyst 2 Overall Analyst 1 Analyst 2 Overall
%CV %CV %CV %CV %CV %CV
LSITGTYDLK 8.30 7.70 8.30 0.61 0.38 0.50
SVLGQLGITK 10.10 5.70 8.30 0.48 0.39 0.43
NFPSPVDAAFR 3.00 7.90 8.40 0.79 0.61 0.71
GGYTLVSGYPK 23.50 20.45 21.80 0.88 0.59 0.76
SAVTALWGK 3.30 4.20 7.20 0.80 0.45 0.64
GTFATLSELHCDK 28.90 39.90 34.60 1.37 0.87 1.14
Cornulin ISPQIQLSGQTEQTQK 21.98 20.80 21.30 0.82 0.51 0.68
LY6 GCVQDEFCTR 13.50 12.50 13.00 0.90 0.44 0.73
WYVVGLAGNAILR 26.50 24.40 26.70 0.33 0.28 0.33
SYPGLTSYLVR 7.00 6.80 7.10 0.49 0.36 0.43
Suprabasin ALDGINSGITHAGR 28.60 21.08 25.70 1.09 0.55 0.86
LSITGTYDLK 16.40 17.30 16.70 0.59 0.94 0.78
SVLGQLGITK 15.30 17.20 16.10 1.00 0.62 0.83
NFPSPVDAAFR 13.10 10.70 11.80 1.08 0.79 0.94
GGYTLVSGYPK 10.50 8.80 9.70 0.90 0.95 0.95
SAVTALWGK 16.20 27.10 39.90 0.88 1.12 1.01
GTFATLSELHCDK 44..2 23.20 39.40 0.79 1.68 1.00
GQNRPGVQTQGQATGSAWVSSYDR 7.80 3.20 89.60 0.94 0.49 0.75
ISPQIQLSGQTEQTQK 7.40 7.50 7.40 0.59 0.43 0.53
LY6 GCVQDEFCTR 7.50 3.50 8.50 1.45 0.44 1.07
WYVVGLAGNAILR 6.20 4.30 5.30 0.24 0.23 0.23
SYPGLTSYLVR 4.30 3.00 3.70 0.62 0.88 0.75
Suprabasin ALDGINSGITHAGR 12.20 12.10 12.60 1.04 0.54 0.82
Statherin FGYGYGPYQPVPEQPLYPQPYQPQYQQYTF 6.10 5.00 5.60 0.19 0.13 0.16
GPYPPGPLAPPQPFGPGFVPPPPPPPYGPGR 3.70 2.60 3.40 0.25 0.18 0.22
IPPPPPAPYGPGIFPPPPPQP 6.70 7.50 7.10 0.36 0.48 0.46
LSGLLDLALGK 6.80 7.80 7.20 0.28 0.32 0.30
IAEYMNHLIDIGVAGFR 3.10 6.70 8.00 0.25 0.23 0.24
PAP ELSELSLLSLYGIHK 25.40 20.20 22.70 0.21 0.22 0.22
IVGGWECEK 24.10 17.30 20.70 1.37 1.15 1.31
LSEPAELTDAVK 21.10 16.30 18.60 0.54 0.34 0.47
DIFTTQDELLVYNK 34.50 31.30 32.70 0.35 0.32 0.34
DVSQSSISFQIEK 24.30 18.70 21.50 0.55 0.38 0.49
TLDEYWR 16.90 45.30 46.50 1.37 1.02 1.23
STEYGEGYACDTDLR 63.80 81.80 79.10 1.15 0.97 1.06





















conceptual amino acid translations of all DNA sequences in GenBank and NCBI RefSeq 
were searched using the PSI-BLAST algorithm to search for position specific matches.  
Results of these database searches are provided in Tables 20-24.  There is some shared 
homology with higher order primates as expected given the close evolutionary relatedness 
of these species to modern humans. Overall, however, there are a subset of select peptides 
for each fluid that are human-specific with no know shared expression in non-human 
primates.  This fact has been taken into consideration in the design of interpretation 
guidelines generated for this multiplex assay.  
Table 20:  Species Specificity of Urine Biomarker Peptides Based on in silico Searches 
Table 21.  Species Specificity of Seminal Fluid Biomarker Peptides based on in silico 
Searches 
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Table 22.  Species Specificity of Saliva Biomarker Peptides Based on in silico Searches 
Table 23. Species Specificity of Vaginal/Menstrual Fluid Biomarker Peptides Based on in 
silico Searches 
Table 24. Species Specificity of Peripheral Blood Biomarker Peptides Based on in silico 
Searches 
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While in silico database searches represent a near exhaustive approach to assessing 
species specificity, additional non-human samples were tested to empirically demonstrate 
the human specificity of target biomarker peptides in this panel.  As hemoglobin is the 
target biomarker that is most widely conserved across non-human mammalian species, 
blood samples from a variety of mammals including domestic pets (dogs and cats) and 
species commonly hunted in the US (bear, turkey, deer, and coyote) were tested.  No peaks 
corresponding to human proteins were detected in any tested samples (Table 25 and 
Figure 22).  
Table 25.  Species Specificity of Peripheral Blood Biomarker Peptides based on empirical 
testing using the QQQ-MRM Assay and non-human blood. 
Figure 22.  Results from the myelin basic protein internal positive control used with the 
non-human blood samples.  Successful digestion of extracted proteins is indicated by the 
presence of digested myelin basic protein (red) and corresponding AQUA peptide standard 
(blue). 
Dog 1 Dog 2 Cat 1 Cat 2 Deer 1 Deer 2  Bear 1  Bear 2 Otter Turkey Coyote
LSITGTYDLK ND ND ND ND ND ND ND ND ND ND ND
SVLGQLGITK ND ND ND ND ND ND ND ND ND ND ND
NFPSPVDAAFR ND ND ND ND ND ND ND ND ND ND ND
GGYTLVSGYPK ND ND ND ND ND ND ND ND ND ND ND
SAVTALWGK ND ND ND ND ND ND ND ND ND ND ND


















3.2.3.6  Mixture Study 
Mixtures prepared at a 1:1 ratio (25 μL total volume) were generated in triplicate 
for all possible pairings of the six targeted biological fluids.  In total, 45 mixed samples 
were tested.  As previously indicated, successful identification of a biological fluid required 
the unambiguous identification of one or more protein biomarker targets.  In 42 of the 45 
samples tested in this study, the assay accurately characterized the fluids present in the 
mixture and did not detect any additional targets that were not present (i.e., no false positive 
results were obtained) (Tables 26-31).    In the remaining three mixture samples, the assay 
failed to identify uromodulin when mixed with semen, menstrual fluid or peripheral blood 
(Table 31).   As described under the sensitivity section of this paper, the assay’s sensitivity 
for the detection of uromodulin was the lowest (i.e., the least sensitive) of all markers 
targeted by the assay while semen and blood (menstrual and peripheral) contain the 
biomarker peptides found in greatest abundance.  Since mixed body fluid samples were 
analyzed on the basis of the total protein concentration of the initial extract, the inability to 
detect the body fluid with a low amount of protein when mixed with a body fluid of high 
protein content is not necessarily unexpected. This is at least in part due to dilution of lower 
abundance protein target as well as potential ion suppression by the high-abundance protein 
biomarker.  
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Sufficient Peripheral Blood 
Markers for Identification 
YES YES YES YES YES 











































Statherin ND ND ND ND 
SubMax 
Amylase 
Sufficient Saliva Markers for 
Identification 
YES YES YES YES YES 
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Sufficient Semen Markers for 
Identification 
YES YES YES YES YES 





































Suprabasin ND ND 
Sufficient Vaginal Fluid Markers 
for Identification 
YES YES YES YES YES 
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Sufficient Menstrual Fluid 
Markers for Identification 
YES YES YES YES YES 




































Urine Uromodulin ND ND ND 
Sufficient Urine Markers for 
Identification 
NO NO YES YES NO 
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3.2.3.7  Casework Samples 
Simulated casework samples were prepared to assess performance of the 
multiplexed body fluid identification assay over a broad range of sample conditions.  Over 
100 samples were prepared which included single-source body fluids, mixed body fluids 
and sexual assault type stains recovered from a variety of substrates (e.g., cotton, denim, 
leather, synthetic fibers, latex and glass).  The potential impact of environmental 
contaminants and potential inhibitory substance (e.g., spermicides, personal lubricants, 
detergent, soil, acids, leather, indigo dye, bleach and tobacco juice) were assessed. To 
explore the impact of degradation, samples were subjected to a variety of environmental 
insults (e.g., aging and known proteolytic enzymes). All casework-type samples were 
prepared and tested in triplicate.   
As shown in Table 32, MRM analysis was able to unambiguously identify 
individual protein components for almost all simulated casework samples.  However, 
mixing neat laundry detergent or 10% bleach with samples resulted in a failure to detect 
any blood-specific proteins.  As is the case with genetic analysis, the development of 
additional front-end sample preparation protocols may enable successful processing of 
these samples (Figure 23).  
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Table 32. QQQ-MRM Detection of Body Fluid Biomarkers in Forensic Casework-Type 
Samples.   
Note:  Dark Green indicates all peptide targets were present.  Light green indicates at least 
1 target peptide was present and at least 1 target peptide was not detected.  Red indicates 
no target peptides were detected.   
Vaginal  
Fluid
Periphera l  
Blood
Sal iva Semen Urine
10 µL on Cotton ND ND ND ND
Finger Swab ND ND ND ND
Peni le Swab ND ND ND ND
10 µL on Cotton ND ND ND
10 µL on Denim ND ND ND
10 µL on Pad ND ND ND
5 µL on Recta l  Swab ND ND ND
50 µL Dried on Spermicide Condom  
col lected with 2% SDS swab
ND ND ND
5 µL plus  5 µL Lubricant Dried on Swab ND ND ND
10 µL on Swab Containing Soi l ND ND ND ND
10 µL on Swab with 10 µL 10% Bleach ND ND ND ND
10 µL on Leather ND ND ND ND
10 µL on swab plus  50 µL Detergent ND ND ND ND
10 µL on Denim ND ND ND ND
10 µL on Cotton ND ND ND ND
Gum ND ND ND ND
50 µL dried on Glass  Bottle  
col lected with 2% SDS swab
ND ND ND ND
10 µL on Cotton ND ND ND ND
10 µL on Condom     
col lected with 2% SDS swab
ND ND ND ND
10 µL Chewing Tobacco Spit Dried on Swab ND ND ND ND
50 µL dried on Condom     
col lected with 2% SDS swab
ND ND ND ND
10 µL on Cotton ND ND ND ND
10 µL on Denim ND ND ND ND
10 µL on Ora l  Swab ND ND ND ND
10 µL on Recta l  Swab ND ND ND ND
50 µL dried on Spermicide Condom  
col lected with 2% SDS swab
ND ND ND ND
5 µL with 5 µL Lubricant on Swab ND ND ND ND
10 µL on Cotton ND ND ND ND
10 µL plus  50 µL Soda on Swab ND ND ND ND
100 µL Dried on Ceramic Cup 
col leted with 2% SDS swab
ND ND ND ND
100 µL Dried on Styrofoam Cup 
col leted with 2% SDS swab






























































Figure 23:  Results obtained for the myelin basic protein internal positive control. Target 
peptides representing bovine myelin basic protein were undetectable in this sample 
consisting of peripheral blood mixed with detergent. This indicates that the digestion of 
peripheral blood proteins that is required to produce the target peptides had failed.    
Given the frequency with which partially degraded samples are encountered by 
forensic practitioners, protein degradation was also evaluated.  The results obtained were 
consistent with those expected, given the published literature which supports the greater 
stability of proteins over time as compared to nucleic acids.  A series of saliva, peripheral 
blood, semen and urine samples which had been aged at room temperature from 2 to 7 
years were analyzed.  As illustrated in Tables 33-36, the MRM assay provided for the 
confident identification of all body fluids based on the presence of at least one and often 
multiple target biomarkers in all aged samples tested.  
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Table 33.  QQQ-MRM Detection of Peripheral Blood Biomarkers Aged Bloodstains 
Table 34.  QQQ-MRM Detection of Saliva Biomarkers Aged Stains 
Table 35.  QQQ-MRM Detection of Seminal Fluid Biomarkers Aged Stains 
Table 36.  QQQ-MRM Detection of Urine Biomarkers Aged Stains 
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3.3  Discussion 
Highly tissue-specific target protein biomarkers for biological fluids of forensic 
interest – namely peripheral blood, semen, saliva, urine, and vaginal/menstrual fluids have 
been identified.  Additionally, the assay targeting these markers has undergone extensive 
developmental validation including an assessment of aged samples, environmental impact, 
species specificity, stability, sensitivity, reproducibility/repeatability, and mixture analysis.  
Overall, it has been demonstrated that a multiplex targeted ion mass spectrometry-based 
assay allows for the serological identification of body fluids most commonly encountered 
in forensic casework. With sufficient gains in sensitivity and specificity, serological 
identification utilizing protein mass spectrometry analysis offers significant advantages 
compared to the existing immunological and biochemical tests currently employed by 
forensic serologists.  
The deliverable to the forensic community following the research presented in this 
chapter includes a functional and developmentally-validated multiplex human body fluid 
identification assay.  This assay has the potential to significantly improve the accuracy and 
sensitivity of serological testing of forensically relevant biological fluids.  While the 
multiplex design of this assay eliminates the need to perform separate tests on an unknown 
stain, however, it requires longer analytical run times and may be unnecessarily 
comprehensive for routine screening of targeted forensic workflows.  The analysis of items 
of items of evidence  from sexual assault kits for example are typically  only screened  for 
semen (and possibly saliva).  The creation of a targeted assay for this specific purpose 
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would allow for faster analytical run times and greater sensitivity for fluids relevant to 
targeted workflows.  
The remaining two chapters of this dissertation will therefore focus on the 
application of a QQQ-MRM assay that has been optimized for analysis of sexual assault 
kit evidence capable of detecting seminal fluid markers.   This approach would enable 
forensic analysts to obtain a confirmatory identification of semen in extended post-coital 
samples. This approach would also allow for the confirmation of semen in samples where 
there was insufficient DNA to obtain an interpretable profile (e.g., vasectomy, lack of 
ejaculation or minimal sexual contact). In short, the conversion of this multiplex assay to 
a fit-for-purpose monoplex assay for the analysis of sexual assault kit evidence would make 
it possible to obtain probative results from samples that might otherwise have yielded 
inconclusive or no results at all, providing the forensic and criminal justice communities 
with a powerful tool to aid the investigation and prosecution of sexual assault. 
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CHAPTER 4: IMPROVING SEMINAL FLUID DETECTION SENSITIVITY IN 
EXTENDED POST-COITAL INTERVALS BY QQQ MASS SPECTROMETRY 
4. Introduction
In 2017, the FBI Crime Statistics reveled that an estimated 135,755 rapes were 
reported to US law enforcement agencies [91]. After several consecutive years of increases, 
the overall number of violent crimes reported according to the FBI figures decreased in 
2017, however, the number of reported aggravated assaults and rapes continued to increase 
by 1.0 and 2.5 percent respectively over 2016 numbers.  Approximately 18% of women in 
the US have been raped in their lifetime [92]. This includes an estimated 1.8 million 
adolescent victims [93]. While the timely recovery of physical evidence is critical to sexual 
assault investigations, many sexual assault victims delay reporting the incident to 
authorities for three to four days after an attack. This is especially true of child victims, 
where disclosure of sexual abuse and rape may be delayed even longer [76].    
The timely recovery of physical evidence of a potential sexual assault is vital. As 
the post-coital interval is extended, the potential for successful identification of probative 
evidence such as seminal fluid and/or DNA diminishes rapidly.  For this reason, the length 
of time after a sexual assault (i.e., the post-coital interval) can influence the potential for 
subsequent forensic testing to yield probative results; the priority assigned to testing a 
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sexual assault evidence kit (especially in the case of backlog reduction efforts); and even 
the decision of whether or not an effort to collect physical evidence of sexual assault will 
be made at all. 
In sexual assault cases, the detection of seminal markers in the vagina or cervix 
constitutes important physical evidence of sexual contact. Accordingly, numerous studies 
have evaluated the persistence of semen in the post-coital interval. Semen, in these studies, 
is usually identified by the presence of spermatozoa although the persistence of 
biochemical markers of seminal fluid (e.g., choline, acid phosphatase, PSA/p30 and 
semenogelin) have also been investigated.  Difficulty in detecting seminal fluid markers, 
sperm and/or DNA past a post-coital interval of 5-7 days, however, has been widely 
reported in the literature [94, 95]. Aside from vasectomized and azoospermic males, semen 
loss due to vaginal lavage, drainage and degradation can all impede the ability to detect 
spermatozoa and/or obtain interpretable DNA typing results. Similarly, these factors limit 
the ability to detect evidence of sexual contact through the use of serological assays that 
indicate the potential presence of seminal fluid.  
There are widely varying estimates of how long into the post-coital interval the 
cellular and biochemical components of semen can be detected. The literature on sperm 
detection in the vagina and cervix exemplifies this. Estimates of the time period within 
which sperm can be recovered from the vaginal cavity of healthy females range from 30 
minutes to 19 days post coitus [96-105]. The majority of authors, however, report finding 
spermatozoa up to 3 days post coitus in the vagina and up to 7 days post coitus in the cervix.  
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Most reports suggesting a 17-19 day post-coital interval for sperm recovery cite two articles 
published in 1891 and 1977; both of which relied on volunteer self-reporting of findings 
that were regarded as “possibly correct” [106]. 
Serological detection of seminal fluid is typically based on antibody-antigen 
interactions (i.e., immunochromatography). PSA/p30 or semenogelin are commonly used 
as the target protein biomarkers. Validation studies using commercial assays suggest that 
spermatozoa persist longer than seminal fluid protein markers.  In one study, post-coital 
vaginal swabs failed to produce positive results for semenogelin or PSA just 3 and 33 hours 
after intercourse, respectively [81]. Even when nylon flocked swabs were used to maximize 
sample release, semenogelin and PSA/p30 were reliably detected only up to 12 hours post-
coitus. In rare cases, positive results were obtained up to 60 hours after intercourse. What 
is important, however, is that in 50% of samples that were negative for semenogelin and 
PSA, partial male DNA profiles were still generated [107]. 
The ability to generate interpretable male DNA profiles at various post-coital 
intervals has also been widely investigated. While DNA profiling can help to establish the 
identity of a male contributor, sexual assault samples often contain an excess of epithelial 
cells from a female victim. This can hinder, or entirely preclude, the detection of the male 
fraction of a mixture when autosomal STRs are used [108].  In such cases, amplification 
of male-targeted Y-STR loci is used. Though Y-STR haplotyping allows for the selective 
isolation of a male profile, the results have a much lower power of discrimination than 
profiling using autosomal markers. In general, however, complete Y-STR haplotypes can 
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be obtained from vaginal/cervical swabs up to approximately 3-4 days post coitus. After 
that, partial profiles continue to be detected up to approximately 5-6 days post-coitus [109-
111].  
The apparent rapid loss of protein indicators of seminal fluid is somewhat 
unexpected given that proteins typically remain stable under conditions that lead to the 
degradation of other biomolecules.  In fact, as previously mentioned proteins are among 
the most long-lasting of all biological molecules having been routinely isolated from even 
ancient biological material [72, 112]. In a forensically applicable study, protein levels 
remained relatively constant even in post-mortem brain tissue [73]. This suggests that the 
difficulty of detecting seminal fluid proteins in the post-coital interval may be due more to 
the sensitivity limits of conventional immunochromatographic assay systems than to the 
loss of the actual target proteins. Antibody-based tests are also subject to both false positive 
and false negative results – the former being due either to the presence of the target seminal 
fluid antigen in non-target body fluids (e.g., female ejaculate [14], breast milk [16], and 
urine [17])(i.e., a true positive for the target biomarker but a false indication of seminal 
fluid) or non-specific binding events such as those triggered by organic acids as indicated 
in chapter 2 (i.e., a true false positive result). Even when successful, however, these tests 
provide only a presumptive indication that seminal fluid may be present. 
A more sensitive and specific technology for the confirmatory identification of 
seminal fluid – one that could match the sensitivity of DNA testing methodologies or even 
identify seminal plasma in vaginal fluid several days after an alleged sexual assault in cases 
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where there is insufficient DNA to obtain an interpretable profile – would provide critical 
physical evidence of sexual contact. With improved sensitivity, forensic examiners would 
have the potential to extend the post-coital interval for sample collection with an improved 
likelihood of successfully obtaining an interpretable DNA profile. 
Selected reaction monitoring (SRM) has a long history of use in the fields of 
toxicology and pharmacokinetics [113]. SRM allows for the specific monitoring of a 
targeted analyte in a complex mixture. Typically, a triple quadrupole-based mass 
spectrometer is employed to achieve this. The first mass analyzing quadrupole of the triple 
quadrupole system allows for the selective passage of a target parent ion by specifying a 
narrow mass window. This parent ion is then fragmented in the second quadrupole, while 
the third quadrupole scans for a desired fragment ion. The identification of both a parent 
and fragment ion (i.e., a transition) provides for high-confidence peptide identification. In 
contrast to SRM strategies, Multiple Reaction Monitoring (MRM) approaches scan for 
several different parent and multiple fragment ions within one run. MRM allows for greater 
productivity over SRM but generally this is achieved at the cost of sensitivity [114].  As 
the number of transitions monitored per assay increases, the dwell time (i.e., the time the 
instrument takes to cycle through the separation and detection of each transition) for each 
targeted ion decreases. Therefore, the more ions targeted, the less time the instrument 
spends detecting and measuring any one ion. This leads unavoidably to an overall decrease 
in sensitivity. 
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A well-established technology for the unambiguous detection of proteins in 
complex biological fluids is triple quadrupole mass spectrometry utilizing multiple reaction 
monitoring (QQQ-MRM). These studies outlined in this chapter have applied a QQQ-
MRM approach to the detection of seminal fluid in cervico-vaginal swabs collected at 
extended post-coital intervals of ≥5 days). The results of this testing were compared to 
existing antibody-based methods to assess the relative utility of a QQQ-MRM approach in 
the analysis of sexual assault samples. 
Narrowing the scope of the multiplex body fluid proteomic assay detailed in 
Chapter 3, the creation of a seminal fluid-specific monoplex assay is expected to enhance 
the sensitivity of the method beyond what has been achieved to date.   Moreover, the 
enhanced sensitivity should allow for the detection of seminal fluid protein markers in 
samples well past the post-coital interval that is attainable with the 
immunochromatographic assays currently used by forensic labs.  The research outlined in 
this chapter therefore aims to: 
 (1) Develop and optimize a monoplex QQQ-MRM assay for seminal fluid using 
single- and mixed-stain swabs that are representative of sexual assault samples. 
(2) Rigorously assess the extended post-coital time limit for which seminal fluid 
biomarkers can be confirmed in sexual assault type samples. 
The successful completion of these aims will facilitate the analysis of challenging sexual 
assault evidence and extend the critical widow within which sexual assault kits can be used 
104 
to collect samples from the victim with a reliable expectation of obtaining probative test 
results. 
4.1  Methods 
4.1.1  Chemicals and Reagents 
Dithiothreitol (DTT), and Iodoacetamide (IAA), and 2,2,2-Trifluoroethanol (TFE) 
were purchased from Sigma-Aldrich (St. Louis, MO).  Mass Spec grade Trypsin gold was 
sourced from Promega (Madison, WI). LCMS grade water acetonitrile, methanol, and 
acetone were purchased from Honeywell/Burdick and Jackson (Muskegon, Michigan). All 
sample preparation was carried out in Eppendorf LoBind Protein microcentrifuge tubes.  
Absolute Quantification (AQUA) C-terminus labelled peptides were custom synthesized 
by New England Peptide (Gardner, MA) and delivered as lyophilized 2 nmol aliquots. 
Intact myelin basic and aprotinin stock solutions (1 mg/mL) were purchased from New 
England Peptide (Gardner, MA) for use as internal positive controls.  
4.1.2 Body Fluid Collection 
Body fluids were collected in accordance with procedures approved by the 
University of Denver’s Institutional Review Board for Research Involving Human Subjects 
as previously described in Chapter 3.  Following collection and processing, all samples 
(peripheral  blood,  menstrual  blood,  vaginal secretions,  semen,  urine and  saliva)  were 
aliquoted into 1.5mL microcentrifuge tubes and stored at -80ºC.  In general, and unless 
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otherwise indicated, 50 µl of blood or 125 µl of all other biological matrices were used for 
the identification of target protein biomarkers.  
4.1.3  LC-MS/MS Analysis 
Optimal parent-fragment ion pairs for high-specificity biomarkers had already been 
identified for semen, saliva, urine, peripheral blood and vaginal/menstrual fluid as 
described previously in Chapter 3. In the original multiplex assay, up to three proteins/fluid 
were selected. Generally, two to three optimal peptides were selected (as parent ions) for 
each protein. Similarly, two to three fragment ions were selected per parent ion. This 
redundancy allowed for greater productivity and selectivity in the multiplex assays. As 
mentioned previously, however, this comes at the cost of sensitivity when using SRM 
assays. 
The primary objective of the work described in this chapter, therefore, was to 
develop and optimize a monoplex QQQ-MRM assay for seminal fluid. This was achieved 
by importing the existing multiplex method but eliminating all biomarker peptides not 
specific to seminal fluid. What remained were the parent-fragment ion pairs for prostatic 
acid phosphatase, prostate specific antigen and semenogelin. Iterations of this method were 
developed in which parent and fragment ion pairs were sequentially eliminated until an 
SRM method with one peptide for each seminal fluid protein biomarker with one fragment 
remained. This was done with the objective of maximizing the dwell time efficiency of the 
instrument; thereby maximizing detection sensitivity. Each of the resulting monoplex assay 
methods was assessed for sensitivity by analyzing vaginal swabs spiked with known 
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quantities of semen. Neat pooled seminal fluid from 10 male donors was diluted at the 
following ratios: 1:800, 1:4,000, and 1:20,000 and digested. After digestion, 125µL 
aliquots were lyophilized and reconstituted for analysis by LC-MS/MS. Each sample was 
analyzed under each of the iterations of the seminal fluid assay. 
Assay specificity was also assessed by analyzing a series of 25 replicate two-, three- 
and four-component mixtures consisting of saliva, semen, vaginal secretions, urine, 
peripheral and/or menstrual blood. The method found to be the most specific for seminal 
fluid with the greatest sensitivity was used for the remainder of the study. 
The second part of the optimization process was to evaluate injection quantity. With 
a multiplex assay, it is difficult to establish a set injection quantity, given the greatly varied 
amounts of targeted protein per matrix. For example, the amount of hemoglobin in a given 
volume of blood is not comparable to the amount of submaxillary gland androgen- 
regulated protein 3B in the same volume of saliva. With one matrix and one sample type 
from sexual assault kits (vaginal, oral and rectal swabs), it is easier to evaluate how much 
protein can be injected without overloading the column. Neat semen (25µL) was added to 
pooled vaginal secretions and quantified for total protein content.  The following amounts 
of total protein were targeted for digestion:  50 µg, 75 µg, 100 µg, 150 µg and 200 µg.  
These amounts were loaded onto 96-well plates for digestion and sample clean-up which 
was performed on the AssayMAP Bravo Platform.  All samples were reconstituted in 2% 
acetonitrile/0.1% formic acid solution to a 1µg/µL concentration and a 10µL aliquot was 
injected on the column.  
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4.1.4  Post-Coital Interval Assessment 
The second objective of the research reported in this chapter was to determine the 
extent to which an optimized monoplex QQQ-MRM assay for semen could be used to 
extend the post-coital interval within which the presence of seminal fluid can be reliably 
detected in cervico-vaginal samples. Typically, these studies employ a self-collection 
swabbing method at various time points after sexual intercourse. However, this introduces 
a great amount of variability into the data set thereby compromising the precision of results 
both amongst and within the sample sets for the individuals participating in the study. 
As it has already been documented in the literature (at least for spermatozoa) that 
seminal persistence is greater at the cervix, this study used cervical swabs obtained by a 
trained sexual assault nurse examiner and collected with a speculum to better represent 
samples that would be generated as part of an authentic sexual assault examination. Two 
swabs at a time were collected from female volunteers after separate acts of sexual 
intercourse at multiple time points (2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 
and 9 days) using sterile nylon flocked applicators. In order to eliminate variability due to 
the combined effect of multiple acts of intercourse, volunteers were asked to abstain from 
intercourse for 12 days prior to the sexual act that was to be followed by sample collection. 
In order to prevent loss of seminal fluid markers from the sampling process itself, only one 
set of swabs was collected after each act of sexual intercourse. All swabs were air dried, 
packaged in sterile paper envelopes and stored at -20°C until extracted for analysis. At least 
two separate collections per post-coital time interval were assessed. 
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4.2 Results 
4.2.1 Development of the Monoplex QQQ-MRM Assay for Seminal Fluid 
The existing six-body fluid multiplex assay was imported and all biomarker 
peptides that were not specific to seminal fluid were eliminated.  What remained were 
parent-fragment ion pairs for prostatic acid phosphatase, prostate specific antigen and 
semenogelin I and II. Iterations of this method were developed in which parent and 
fragment ion pairs were sequentially eliminated in order to maximize the dwell time 
efficiency of the instrument; thereby maximizing detection sensitivity while maintaining 
assay specificity.  Additional biomarkers, not part of the original six-body fluid multiplex 
assay, were also incorporated into the methods to further optimize the specificity and 
sensitivity. These markers, many of which were high quality target biomarkers, had 
originally been eliminated due to the fact that they generated assay interference because 
they coeluted with protein biomarker targets from other biological fluids that the assay was 
looking for at approximately the same retention time. Since the detection of these other 
body  fluids was  no longer  part of the  seminal fluid assay,  the concerns  associated with 
coeluting species were eliminated and the potential utility of these biomarker targets could 
be reevaluated.  Targets incorporated into the various iterations of the monoplex seminal 
fluid assay as well as their respective specificities can be found in Table 37.  
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Table 37.  Peptide Targets Evaluated for the Development of the Monplex QQQ-MRM 
Seminal Fluid Assay.  
Note:  Those peptides abbreviated with a “*” were not part of the original 6 fluid multiplex 
assay and reincorporated for evaluation with the seminal fluid assays.   
The most abundant peptides per protein were selected based on preliminary 
qualitative studies. A scheduled and unscheduled method incorporating all target peptides 
identified in Table 37 was first compared.  A scheduled method utilizes retention time 
windows in order to target specific transitions at a precise retention time. This is an 
alternate strategy for decreasing dwell time (Figure 24).  Four additional paired down 
scheduled methods were also assessed.  
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Figure 24.  Scheduled (bottom) versus unscheduled (top) methods of analysis on an LC-
MS/MS.  During an unscheduled method, the instrument filters and scans for all targets 
throughout the entirety of the run.  During a scheduled method, detection windows are set 
based on retention times for each fragment, allowing the instrument to scan and filter for 
those target analytes only during specified periods of time during the run, decreasing dwell 
time of the method and therefore increasing overall sensitivity.   
When comparing results from the unscheduled and scheduled methods, significant 
improvements in sensitivity were observed with the scheduled method (Figure 25). An 
ANOVA with a 95% confidence interval was performed on normalized peak areas for each 
peptide across all 6 methods evaluated (1 unscheduled and 5 scheduled) to determine 
statistical significance.  Significant differences between methods were observed for all  but 
the FQEL peptide of the prostatic acid phosphatase protein (ELSE: Fs=33.833; df=2,6; 
P=5.40e-4, IVGG: Fs=28.338; df=2,6; P=8.77e-4, LSEP: Fs=23.207, df=4,10; P=4.79e-5, 
DIFS: Fs=9.625; df=5,12; P=0.0007, LPSE: Fs=51.291; df=3,8; P=1.438e-5, DVSQ: 
Fs=6.736; df=5,12; P=0.0032, DIFT: Fs=5.693; df=3,8; P=0.0219; FQEL: Fs=2.947; 
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df=1,4; P=0.1611). A post-hoc Tukey test with a 95% confidence interval showed that all 
scheduled methods evaluated produced significantly greater peak areas and intensities for 
all peptides as compared to the unscheduled method while no statistical differences of mean 
peak areas were observed between any scheduled methods assessed in which parent and 
fragment ion pairs were eliminated with the exception of the LPSE peptide for SgI 
(Appendix II).  Given that scheduled methods were employed and that there was no 
coelution of targets in the method, this was an expected outcome. 
Figure 25. Chromatographic comparison of the unscheduled and scheduled methods for 
the Semenogelin II peptide DVSQ. The peak intensities are labeled in the upper right hand 
corner of each chromatogram.  
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Assay specificity was assessed by analyzing a series of at least 25 replicate two-, 
three- and four-component mixtures consisting of saliva, semen, urine, peripheral blood 
and vaginal/menstrual fluids (Figure 26). Since no significant difference in sensitivity was 
observed amongst scheduled methods, specificity only needed to be assessed for the 






Figure 26. Two component (A), three component (B) and four component (C) mixtures 
containing combinations of menstrual blood (MB), peripheral blood (PB), saliva (SA), 
vaginal secretions (VS), urine (UR), and semen (SE).  Green boxes indicate the presence 
of a peptide at a detectible level and red boxes indicate the absence of a peptide at a 
detectible level.  Bolded boarders indicate where positive results were expected based on 
mixture composition.   
Prostatic acid phosphatase had multiple peptides that failed to be detected in 
samples that contained semen (samples not shown). At the same time, these peptides were 
detected in samples that did not contain semen.  In all instances where prostatic acid 
phosphatase was detected in a mixture that did not contain seminal fluid, vaginal secretions 
were present in the mixture.  This is consistent with the published literature which indicates 
the presence of acid phosphatase in vaginal secretions albeit at lower concentrations than 
seminal fluid.  Epididymal secretory protein was also identified in two samples containing 
semen-free vaginal fluid.  Given the lack of observed specificity of these two biomarkers, 
all peptides for both prostatic acid phosphatase and epididymal secretory protein were 
eliminated from the final seminal fluid assay. The final method, therefore, that was found 
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to be most specific for seminal fluid and which had the greatest sensitivity is included in 
Appendix III.  This method was used for the remainder of the study. 
A sensitivity comparison of the monoplex assay to the original multiplex assay for 
all six biological fluids demonstrated a gain in sensitivity of nearly one order of magnitude.  
The original multiplex was able to detect a pooled sample of seminal fluid at a dilution of 
1:16,384 while the optimized monoplex assay for seminal fluid was able to detect seminal 
fluid at a dilution of 1:131,072 (Figure 27).  
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(A) (B) 
Figure 27.  (A) Sensitivity limits of seminal fluid for the original multiplex assay for six 
forensically relevant biological fluids.  (B). Sensitivity limits for semen using the optimized 
monoplex assay for seminal fluid representing a three-fold increase in sensitivity obtained 
for seminal fluid.    
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An evaluation was made to determine the total amount of protein can be loaded on 
the sample preparation robotic platform (Agilent AssayMAP Bravo) for injection onto the 
LC-MS/MS instrument.  To achieve this, peak areas for targeted peptides were assessed 
for overall abundance.  A decrease in peak abundance with an increase in total protein 
targeted for digestion indicates C18 cartridge overload on the robotic platform.  The C18 
cartridges on the robotic platform use a hydrophobic sorbent phase to retain peptide 
fragments.  As more protein is loaded onto the sorbent phase, preferential binding of 
hydrophobic peptides and concurrent loss of hydrophilic peptides will occur.  As the more 
abundant seminal fluid peptides in the final assay are hydrophilic, this would result in 
decreased assay sensitivity.  Based on the results of these experiments the optimum protein 
loading quantity was determined to be 100 µg based on observations made of all peak areas 
for protein targets (Figure 28).   
Figure 28.  Peptide abundance as measured by average peak area compared to total protein 
loading amount on the C18 cartridge.  As the peptides for epididymal secretory protein are 
the most hydrophilic, they were used to assess when preferential binding on the C18 
cartridge occurred.   
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4.2.3. Assessment of the Sensitivity of the Monoplex QQQ-MRM Assay for Seminal 
Fluid Using Authentic Post-Coital Cervico-Vaginal Samples 
The extent to which the optimized monoplex QQQ-MRM assay for semen could 
extend the post-coital interval during which the presence of seminal fluid could be reliably 
detected in cervico-vaginal samples was assessed. A small cutting from each swab was 
collected and placed in 500 µl of Universal Buffer (Independent Forensics).  This solution 
contains buffer and salts (Tris, NaCl, KCl) for physiological stability, a chelating agent 
(EDTA) for stability, detergents and surfactants (Triton X-100 and Tween 20) for 
extraction efficiency and solubility maintenance, protein (BSA) for reducing non-specific 
adsorption and loss and a preservative (sodium azide).  Following a 30-minute incubation 
at room temperature with agitation, manufacturer recommended volumes were tested using 
ABAcard® p30 (Abacus Diagnositcs), RSID™-Semen (Independent Forensics), and PSA 
Semiquant (Seratec).  Consistent with the published literature, the ability to generate 
positive results for seminal fluid (with one exception) using immunochromatographic 
assays were lost at just 48 hours post-coitus (Table 38).  Analysis of authentic post-coital 
cervico-vaginal swabs using the QQQ-MRM monoplex assay for seminal fluid, however, 
was demonstrated to greatly extend the post-coital interval of detection for seminal fluid.  
Semen in the same paired samples was detected up to 8 days post-coitus using the QQQ-
MRM assay, not only far exceeding the sensitivity of commercial antibody-based methods 
but matching and exceeding that reported for DNA-based approaches (Table 39). 
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Table 38. Immunochromatographic Results for Seminal Fluid using the RSID™ Semen 
(semenogelin) and the ABAcard® p30 and PSA Semiquant (PSA/p30) Assays Kits.   
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Table 39.  QQQ-MRM Assay Results for Seminal Fluid Protein Targets PSA/p30 and 
Semenogelin I and II.   
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4.3 Discussion 
For these experiments, a monoplex (single body fluid) QQQ-MRM assay was 
developed to enhance the sensitivity of seminal fluid detection beyond that of both the 
multiplex method and contemporary immunochromatographic assays. By eliminating from 
the multiplex, proteins not specific to seminal fluid and adding additional seminal fluid 
proteins that had not previously been used, the resulting monoplex assay maximized 
instrument dwell time efficiency and thus detection sensitivity. The sensitivity limit for this 
new seminal fluid specific assay was such that a 1 to 131,072 dilution of seminal fluid 
could be confidently detected.  Application of the optimized assay to two-, three- and four-
component mixtures of semen, vaginal and menstrual fluids, saliva, urine, and peripheral 
blood showed it to be highly sensitive and specific for human seminal fluid. Analysis of 
authentic post-coital cervico-vaginal swabs demonstrated that the enhanced sensitivity of 
the QQQ-MRM assay far exceeded that of commercial antibody-based methods as 
illustrated by the detection of semen in authentic vaginal swabs collected up to 8 days post 
coitus. With a level of sensitivity that is equal to or greater than that of Y-STR DNA 
analysis, comes the need to better understand how quantitative levels of semen peptides 
might correlate with recoverable male DNA. A “peptide cutoff/threshold level” for 
example may aid forensic analysts in assessing the likelihood of obtaining an interpretable 
male DNA profile from the remainder of the sample extract. Similarly, such quantitative 
thresholds could be used for paired analyses of seminal fluid-free vaginal swabs (i.e., 
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QQQ-MRM vs. immunochromatography) to better estimate the actual rate of false 
positives in widely used serological tests. 
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CHAPTER 5: QUANTITATIVE SEMINAL FLUID DETECTION BY MASS 
SPECTROMETRY AS AN INDICATOR OF MALE DNA PROFILING SUCCESS 
AT EXTENDED POST-COITAL INTERVALS 
5. Introduction
Despite their prevalence, sexual assault kit (SAK) samples can often be among the 
more challenging samples handled by forensic laboratories. Using standard autosomal 
short tandem repeat (STR) DNA profiling, an abundance of female DNA on intimate swabs 
can mask the presence of trace quantities of male DNA. While this can be overcome by 
using male-targeted Y- STR profiling/haplotyping, the statistical weight of a Y-STR match 
is typically a tiny fraction of that calculated for an autosomal match. PCR inhibitors from 
bacteria, blood, fecal matter and/or other chemical compounds may be present which 
impede DNA amplification. Finally, SAK samples encompass wide variation with regard 
to the age and quality of the biological material. These factors alone – or in combination – 
can make it difficult to generate an informative male DNA profile or haplotype using either 
autosomal or Y-STR chemistries. In fact, many SAK samples fail to produce any detectable 
male DNA at all [115].  As a result, forensic practitioners have long relied on traditional 
serological screening as a means of identifying those samples that are the best candidates 
for successful DNA profiling. 
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Traditional workflows for the processing of SAK samples have relied upon enzyme 
activity and antibody-binding based serological tests for the detection of seminal fluid 
and/or saliva as well as microscopy for the detection of spermatozoa. The laborious nature 
of performing multiple serological assays to screen evidence and the uncertainty associated 
with what are typically presumptive results, however, have contributed to increased 
popularity of Y-screen assays as an alternative workflow for SAK samples. 
Currently, many forensic laboratories use one of two Y-screen workflows. In the 
first approach, all samples undergo differential extraction to enrich for sperm cells followed 
by male DNA quantitation to select samples for advancement to genetic profiling.  In the 
second approach, rapid lysis of a test cutting is followed by male DNA quantitation to 
prioritize samples for differential extraction and genetic profiling. While both approaches 
achieve rapid screening for the presence of a detectible male contributor, they require that 
either laborious differential extraction be used for all samples or multiple cuttings be 
extracted/quantified for each item. More critically, though, neither method provides 
investigators with any serological information. The resulting lack of critical 
investigative/biological context, opens the door to alternative explanations for the presence 
of the male DNA (e.g., secondary/indirect transfer of trace DNA from skin cells or cell-
free DNA sources [116-118]). In these increasingly common types of cases involving trace 
DNA profiles, the ability to detect semen provides both investigators and the trier of fact 
with critical context for evaluating what are often the contradictory claims of the victim 
and the defendant. 
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Traditional serological assays, however, lack comparable sensitivity to that of Y-
screen workflows meaning that many SAK samples that yield interpretable DNA profiles 
would not likely yield useful serological information even if they were tested. In addition 
to the sensitivity limitations associated with degradation, dilution and visual interpretation 
of immunochromatographic assays for PSA or Sg I/II, false positive indications of seminal 
fluid may also arise due to the presence of the target antigen in biological fluids other than 
semen, cross-reactivity or other non-specific antibody binding events. This underscores the 
presumptive nature of these assays.  The PSA glycoprotein, for example, is a serine 
protease [119] secreted by the prostate that cleaves semenogelin [120]. This is responsible 
for the liquefaction of seminal fluid. PSA is present in seminal fluid at concentrations that 
range from 0.2 to 5.5 mg/mL [85, 121]. While PSA concentrations are highest in seminal 
fluid, however, it is also present in vaginal fluid (originating from the periurethral gland 
that is homologous to the prostate [14]), albeit at what are typically lower levels [16, 121-
125]. Saliva, serum, breast milk and amniotic fluid also contain low levels of PSA (Table 
40).  Based on these reported concentrations, however, only breast milk and amniotic fluid 
may contain sufficient PSA concentrations to produce a positive test result using lateral 
flow assays designed for seminal fluid detection.  Similarly, the Sg I/II proteins originate 
mostly from the seminal vesicle and are the main component of semen coagulum [126]. 
While Sg I/II concentrations are highest in seminal fluid (10 to 20 mg/mL) [126], it too is 
not semen specific. Transcripts for Sg I have been found in the gastrointestinal tract 
including tissues of the throat and skeletal muscle while transcripts for Sg II have been 
found in kidney tissue.  Based on the reported concentrations of PSA and Sg in other fluids, 
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however, it is unclear as to whether false positive results on lateral flow assays with non-
target body fluids are been due to trace but detectible levels of these proteins or due to non-
specific antibody binding events akin to those demonstrated in Chapter 2 of this 
dissertation.  Regardless, the need for an enhanced approach to screening SAK samples 
which simultaneously provides both a reliable means of selecting/prioritizing samples for 
DNA profiling as well as reliable serological information has been demonstrated. 
Table 40.  PSA Concentrations in Biological Matrices other than Seminal Fluid. 
It has already been demonstrated that a QQQ-MRM assay for the detection of 
seminal fluid provides enhanced detection sensitivity and accuracy relative to 
immunochromatography. This approach (which need not consume cellular DNA) allows 
the detection of seminal fluid in authentic vaginal swabs past the reported post-coital 
interval for Y-STR DNA typing. Thus, the overarching goal of this research was to glean 
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additional practitioner-relevant information through a quantitative analysis of sexual 
assault samples collected across a wide post-coital interval. 
To achieve this, an already robust qualitative QQQ-MRM assay for seminal fluid 
was converted into a quantitative assay. Absolute quantitation was achieved through the 
use of intact protein and isotopically labeled synthetic peptide internal standards [127] for 
multiple peptides from the same protein [128]. Then, by comparing quantitative protein 
data with genetic data from Y-STR testing of the same samples, it was possible to assess 
the degree of correlation between the detection of a given quantity of targeted seminal fluid 
proteins and the success rates for obtaining a male Y-STR profile. Additional studies 
focused on assessing the rate and potential impact of true false positive 
immunochromatographic results with casework-type samples. A true false positive result 
is defined as a false positive due to non-specific antibody interactions rather than a positive 
result arising as a result of target protein expression in a non-target tissue (i.e., the detection 
of a seminal fluid biomarker protein expressed in a body fluid other than seminal fluid). 
These goals were achieved through the successful completion of the following three core 
research objectives: 
(1) A quantitative QQQ-MRM assay was developed and optimized using synthetic 
PSA and Sg I/II proteins to establish a standard curve which was then used to 
quantitate these proteins in forensic-type samples. 
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(2) The correlation between peptide quantitative values for target seminal fluid peptides 
and the ability to generate Y-STR profiles from vaginal swabs collected at various 
post-coital intervals was assessed.  
(3) The rate of false positive results associated with immunochromatographic tests of 
semen-fee vaginal swabs was determined to assess whether target proteins in the 
sample were actually present above the assay’s sensitivity threshold. 
5.1  Methods 
5.1.1 Development of an Absolute Quantitative QQQ-MRM Assay for Seminal Fluid 
Known concentrations of PSA/p30 and Sg were added to vaginal secretions and 
digested with trypsin. Synthetic isotope-labeled peptides retain the chemical and 
chromatographic properties of natural peptides but have a mass shift due to the introduction 
of a stable “heavy” isotope. These “heavy” peptides were added to samples at a fixed 
concentration and the ratio of the target peptide recovered from a standard to the synthetic 
labeled peptides was plotted against the known concentration to generate a linear standard 
curve. The response of a natural peptide in a test sample was normalized to the “heavy” 
standard in order to calculate its concentration from the standard curve [129, 130]. 
Non-matrix curves for each peptide were used to select protein standard and labeled 
peptide concentrations for the in-matrix curve. A fit-for-purpose analytical method 
assessment was then performed in order to assess the performance of the assay.  This 
included evaluating the linearity/calibration model, limit of detection (LOD), and limit of 
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quantitation (LOQ).  A straight fit line using weighted linear regression with inverse 
concentration-squared weights was used to evaluate the working range.  Acceptable criteria 
for these parameters included correlation coefficient >0.98.  LOD was assessed using three 
blank pooled vaginal matrix samples analyzed over three runs concurrently with fortified 
serial dilutions of the lowest standard. The LOD was defined as the lowest concentration 
yielding an average signal:noise ratio greater than 3. The precision and accuracy of the LOQ 
was evaluated across a three-day reproducibility study from three separate sources of blank 
vaginal swabs. An acceptable LOQ level was defined as a %CV within 20% of the 
calculated mean and within 20% of the target (0.5 fmol/µl). 
5.1.2  Assessment of the Relationship between Quantitative Levels of Target Seminal 
Fluid Peptides and the Generation of Y-STR Profiles from Post-Coital Vaginal Swabs 
Self-collected vaginal swabs were collected at various post-coital intervals (2 swabs 
per sample) from study participants who completed a survey indicating the time since their 
last known act of barrier-free sexual intercourse. Fifty (50) self-collected post coital vaginal 
samples were tested. 
Each self-collected post coital vaginal swab was solubilized in 1mL of deionized 
water for 30 minutes at room temperature with periodic vortexing.  Swabs were then placed 
into spin basket inserts and centrifuged at 1200 RPM for 10 minutes to pellet cellular 
material. After centrifugation, the swab cutting and spin baskets were removed.  The 
supernatant was transferred to a clean 1.5mL microcentrifuge tube and cuttings were placed 
back into pelleted material and retained.  For the QQQ-MRM analyses, 100 µl of extract 
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(i.e., the supernatant) was used.  To ensure quantitative concordance, swabs were analyzed 
in duplicate by quantitative QQQ-MRM and the values averaged to determine the 
concentrations of target seminal fluid proteins. 
The pelleted material and cuttings underwent DNA extraction utilizing an 
AutoMate Express Robotic Extraction platform (Thermo Fisher Scientific) and the 
PrepFiler Express chemistry (Thermo Fisher Scientific).  All samples were eluted in a final 
volume of 100 µl.  All DNA extracts were quantified by Quantifiler® Trio and typed using 
Yfiler® Plus chemistries (Thermo Fisher Scientific) on a 3500 Genetic Analyzer. The 
resulting data were analyzed with GeneMapper IDX Software. The analytical thresholds 
(AT) applied for profile interpretation were based on previous validation studies that 
independently evaluated the S/N characteristics for each dye channel.  For a 15 second 
injection the AT values used were blue:  40 RFU; green:  55 RFU; yellow:  50 RFU; purple:  
50 RFU; and red:  50 RFU.  Seminal fluid protein content was compared to the percent of 
Y-STR loci in order to determine the seminal fluid peptide concentration at which Y-STR 
typing consistently failed to yield interpretable results. 
5.1.3 Estimation of the Rate of Authentic False Positive Results Associated with 
Immunochromatographic Assays for Seminal Fluid 
Self-collected vaginal swabs (2 swabs/sample) were collected from ≥50 
participants who were not engaging in barrier-free vaginal intercourse and who indicated 
that it has been at least 1 month since the last known act of condomless sexual intercourse. 
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A matrix blank (pooled vaginal fluid) and positive semen control was analyzed with each 
batch of samples.  
Each full swab was solubilized in 1mL Universal Buffer (Independent Forensics) 
for 30 minutes at room temperature with periodic vortexing.  Swabs were then placed into 
spin basket inserts and centrifuged at 1200 RPM for 10 minutes to pellet the cellular 
material. Following centrifugation, the cutting and baskets were removed and discarded.  
The supernatant was transferred to a clean 1.5mL microcentrifuge tube and pelleted 
material was retained.  The samples were analyzed per the manufacturer’s instructions for 
the RSID Semen (Independent Forensics),  PSA SemiQuant® (Seratec), and ABAcard p30 
(Abacus Diagnostics) immunochromatographic assays; 100 µl extract was placed in the 
sample window of the cassette for RSID Semen and 200 µl extract was placed in the sample 
window of the cassette for ABACard p30 and PSA SemiQuant®. The remaining 
supernatant was prepared for analysis by the QQQ-MRM method.   
As the purpose of this objective was to evaluate the rate of true false positive 
reactions obtained with the immunochromatographic assays being analyzed, normal testing 
procedures that closely followed those recommended by manufacturers were desired.  It is 
for that reason that swabs were solubilized in Universal Buffer instead of water as per 
internal standard operating procedures for QQQ-MRM sample preparation.  This required 
the addition of an initial solid phase extraction for the 100 µl sample extract prior to 
digestion and introduction to the LC system in order to prevent the introduction of 
detergents to the LC column.  
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Any samples producing positive results on any of the immunochromatographic 
assay were evaluated to determine whether the target protein was actually present at levels 
above the reported sensitivity limits of the lateral flow tests. If the mass spectrometry 
results indicate a target protein concentration below the sensitivity limits, the result will be 
considered a false positive event (pelleted material from swabs was also saved to confirm 
the absence of sperm cells using Sperm HyLiter). For any samples with positive QQQ-
MRM results (i.e., a target peptide concentration above the LOQ) were analyzed in 
duplicate and the values averaged to determine the concentrations of target seminal fluid 
proteins and to ensure quantitative concordance between measurements.  
5.2  Results 
5.2.1  Development of an Absolute Quantitative QQQ-MRM Assay for Seminal Fluid 
The ratio of the synthetic isotope-labeled “heavy” vs. the “natural” peptide was 
plotted against known peptide concentrations to generate a linear standard curve for 
absolute quantitation. Similarly, with any case-type sample tested in a forensic context, the 
response of the tryptic “natural” peptide vs. the “heavy” standard can be used to calculate 
its concentration from the standard curve. 
Initially, neat or non-matrix curves for each peptide were generated in order to 
establish an analytic measurement range (AMR) for the analytical assay. Calibrators were 
generated in 2% acetonitrile with 0.1% formic acid at the following levels: 0.5 fmol/µL, 1 
fmol/µL, 5 fmol/µL, 10 fmol/µL, 25 fmol/µL, 50 fmol/µL, and 100 fmol/µL with the 
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isotopically labelled internal standards added at 25 fmol/µL. Linear calibration curves with 
a weighting factor of 1/2 were generated for each peptide, producing a correlation 
coefficients of 0.99 or greater. 
In-matrix curves (i.e., in vaginal fluid) were then assessed to ensure the reliability 
of the analytical method. This performance check assessed the calibration model, LOD, 
and LOQ over the course of three days to verify reproducibility and performance. 
The calibration model was assessed from three separate calibration curves 
generated over three separate days. The intercept and linearity/R2 were assessed for each 
peptide within the scope of the analytical method. All compounds performed adequately 
with R2 values of >0.99 across all test batches (Table 41 and Figure 29). 
Table 41.  Assessment of the Analytical Calibration Model.  
Calibration Model Assessment 
Compound R2 Intercept 
Semenogelin QITIPSQEQEHSQK 0.99 0.00 
Semenogelin GSISIQTEEQIHGK 0.99 0.01 
PSA LSEPAELTDAVK 0.99 0.00 
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Figure 29.  Linear calibration models for all peptides within the scope of the analytical 
method.   
The LOQ was assessed by analyzing three separate sources of blank matrices in 
triplicate over three days. Each of these values was quantified against a calibration curve 
prepared on that same day in order to determine the method bias and precision. Method 
bias, which was measured as the % difference from the target concentration (0.5 fmol/ µL), 
was below 15% for all target analytes. Similarly, precision variation was below 15% 
showing acceptable LOQ reproducibility (Table 42).  Representative chromatograms for 
each target are shown in Figure 30.  The final quantitative QQQ-MRM seminal fluid assay 
method parameters are detailed in Appendix III. 
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Table 42:  Limit of quantitation assessment 
Limit of Quantitation Assessment 
Compound Bias (% Difference) Precision (%CV) 
Semenogelin QITIPSQEQEHSQK 12.9 7.7 
Semenogelin GSISIQTEEQIHGK 3.0 4.7 
PSA LSEPAELTDAVK  1.3 14.7 
Figure 30.  Chromatogram for each target analyte at the limit of detection and 
quantitation.   
5.2.2 Assessment of the Relationship between Quantitative Levels of Target Seminal 
Fluid Peptides and the Generation of Y-STR Profiles from Post-Coital Vaginal Swabs 
Seminal fluid protein concentrations were compared to the percent of Y-STR loci 
detected (out of a total of 27 loci) to determine whether there was a consistent relationship 
between seminal fluid peptide concentrations and Y-STR haplotyping success (Table 43).   
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Out of the 50 samples analyzed, there was full concordance in all but 2 instances between 
the QQQ-MRM target peptide concentrations and the ability to produce interpretable Y-
STR profiles when targeting the semenogelin I peptide target (QITI peptide).  The PSA/p30 
peptide target (LSEP peptide) did not perform as well as the semenogelin peptide targets.  
In these two instances (samples number 22 and 25) partial DNA profiles were produced 
with 67% and 52% of donor alleles detected above the applied analytical thresholds 
respectively. In these two samples however, no target seminal fluid peptides were detected.  
In all other instances, when no Y-STR donor alleles were detected, no target peptides were 
detected either. Conversely, when full and partial Y-STR profiles were produced the QITI 
peptide was detected above the LOQ and could be reliably quantified.   In three instances, 
Y-STR profiles were obtained within a defined “uninformative range” (between 2 to 5 
alleles produced).  In these three instances, mixed results were obtained for both 
semenogelin targets.  In two instances both the QITI and GSIS peptides were detected 
above the LOQ and in 1 instance they were not detected.  
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Table 43. Relationship Between Target Protein Quantity and Y-STR Profiling Success in 
Post-Coital Vaginal Swabs.   
Note: Days post coitus was self-reported in the sample questionnaire that accompanied 
















1 1 Full (26 alleles) 100 11.257 1.67 (-)
2 1 Full (26 alleles) 100 3.582 0.6244 (-)
3 1 Full  (27 alleles) 100 25.8335 9.7626 (-)
4 1 Full  (27 alleles) 100 33.0449 10.617 (-)
5 1 Full (27 alleles) 100 424.9819 35.5791 0.9348
6 1 Full (27 alleles) 100 1416.9186 199.8537 2.2256
7 1 Full (27 alleles) 100 1.4199 0.9801 0.6485
8 1 Full (27 alleles) 100 2.4021 1.8503 1.4456
9 1 Full (27 alleles) 100 11.7173 7.525 5.0878
10 1 Full  (26 alleles) 100 1.0639 0.8321 1.6974
11 1 Full  (26 alleles) 100 0.8404 0.7073 1.4372
12 2 Full (27 alleles) 100 1.0763 0.8259 0.5832
13 2 Full (27 alleles) 100 132.1065 36.4736 (-)
14 Unknown Full (26 alleles) 100 1.587 0.8126 (-)
15 2 Full (27 alleles) 100 88.8538 19.1607 (-)
16 3 Full (27 alleles) 100 8.5282 4.5612 (-)
17 3 Full (27 alleles) 100 5.2404 2.8667 (-)
18 3 Full  (26 alleles) 100 1.9207 (-) (-)
19 3 Full  (26 alleles) 100 1.399 (-) (-)
20 2 Partial (22 alleles) 81 0.9687 0.8106 0.6412
21 3 Partial  (19 alleles) 70 0.854 1.5641 (-)
22 2 Partial  (18 alleles) 67 (-) (-) (-)
23 3 Partial (17 alleles) 63 1.0265 0.9836 0.7347
24 3 Partial (17 alleles) 63 0.9473 0.7499 0.5549
25 2 Partial  (14 alleles) 52 (-) (-) (-)
26 3 Partial  (6 alleles) 22 1.098 2.8809 (-)
27 4 Partial (5 alleles) 18 1.5929 1.4179 (-)
28 5 Partial (4 alleles) 15 (-) (-) (-)
29 2 Partial (2 alleles) 8 0.5471 0.5202 (-)
30 4 1 Allele Detected 4 (-) (-) (-)
31 4 1 Allele Detected 4 (-) (-) (-)
32 4 1 Allele Detected 4 (-) (-) (-)
33 7 1 Allele Detected 4 (-) (-) (-)
34 7 1 Allele Detected 4 (-) (-) (-)
35 3 No Alleles Detected 0 (-) (-) (-)
36 3 No Alleles Detected 0 (-) (-) (-)
37 3 No Alleles Detected 0 (-) (-) (-)
38 4 No Alleles Detected 0 (-) (-) (-)
39 4 No Alleles Detected 0 (-) (-) (-)
40 4 No Alleles Detected 0 (-) (-) (-)
41 4 No Alleles Detected 0 (-) (-) (-)
42 4 No Alleles Detected 0 (-) (-) (-)
43 4 No Alleles Detected 0 (-) (-) (-)
44 5 No Alleles Detected 0 (-) (-) (-)
45 5 No Alleles Detected 0 (-) (-) (-)
46 5 No Alleles Detected 0 (-) (-) (-)
47 6 No Alleles Detected 0 (-) (-) (-)
48 6 No Alleles Detected 0 (-) (-) (-)
49 8 No Alleles Detected 0 (-) (-) (-)
50 8 No Alleles Detected 0 (-) (-) (-)
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observed donor alleles detected by the number of donor alleles expected.  Green boxes 
indicate a positive result (for YSTR results, this is represented by the detection of 6 or more 
donor alleles; for the QQQ-MRM results, this is represented by the quantitative value of a 
target peptide).  Red boxes indicate the absence of a peptide at a detectible level on the 
QQQ-MRM method and 1 or fewer donor alleles detected.  Yellow boxes denote partial 
Y-STR profiles falling within the uninformative range of 2 to 5 donor alleles detected. 
5.2.3 Estimation of the Rate of Authentic False Positive Results Associated with 
Immunochromatographic Assays for Seminal Fluid 
Originally, this research proposed to analyze 50 negative vaginal swabs, however, 
in order to confirm these findings, an additional batch of 50 negative vaginal swabs (for a 
total of 100 samples) was tested.  Out of the 100 samples analyzed, 17 produced false 
positive results for ABAcard p30 and PSA Semiquant while 6 produced false positive 
results for RSID Semen resulting in a 17% and 6% false positive rate respectively.  
Interestingly, in no instance, did a sample produce a false positive result on all three 
immunochromatographic assays. It was also not always the case that a sample which 
produced a false positive on one assay targeting PSA (ABAcard p30 or PSA Semiquant) 
would necessarily produce a false positive result on the other assay targeting PSA.  
Subsequent analyses of these presumed false positive samples by mass 
spectrometry did not detect the presence of the protein targets for any of the 
immunochromatographic assays that were evaluated. This renders more probable the 
inference that prostate specific antigen and semenogelin proteins were either not present in 
these samples or were present at such low levels that one would not expect to detect them 
by immunochromatography (Tables 44-45; Figure 31).  
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Additionally, all cellular components of the 26 samples that produced positive 
immunochromatographic results were confirmed to be sperm free utilizing Sperm HyLiter 
and fluorescent microscopy.  This, coupled with the quantitative QQQ-MRM results 
indicates that the positive immunochromatographic results were likely to be true false 
positive non-specific binding events rather than an unexpected positive result due to the 
presence of the target proteins at low levels in these particular samples.  These data 
underscore the presumptive nature of immunochromatographic assay results and should 
alert forensic practitioners to the fact that the rate of true false positive results is not 
insubstantial.   
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Table 44. Batch 1 of “seminal fluid free” vaginal swabs.  
Note: Green boxes indicate a positive test result (for the immunochromatographic assays 
means a line both at the control and the test zones; for the QQQ-MRM assay, this means a 
target peptide quantity above the LOQ).  Red boxes indicate the absence of a peptide at a 
detectible level on the QQQ-MRM assay and a negative test result on the 
immunochromatographic assays.  Gray boxes indicate the sample was not tested.   
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Table 45. Batch 2 of “seminal fluid free” vaginal swabs.  
Note: Green boxes indicate a positive test result (for the immunochromatographic assays 
means a line both at the control and the test zones; for the QQQ-MRM assay, this means a 
target peptide quantity above the LOQ).  Red boxes indicate the absence of a peptide at a 
detectible level on the QQQ-MRM assay and a negative test result on the 
immunochromatographic assays.  Gray boxes indicate the sample was not tested   
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Figure 31.  Sample images of false positive results obtained following testing of semen-
free vaginal swabs using multiple commercial immunochromatographic assays designed 
to target PSA (Seratec Semiquant and ABAcard) or Sg (RSID Semen) in seminal fluid 
illustrating the range of strong to weak false positive results obtained.   
5.3 Discussion
The data outlined in this chapter illustrate how the use of high-sensitivity targeted-
ion mass spectrometry can be used to not only address the limitations of existing methods 
for semen detection but also to establish a framework for the use of quantitative 
information on seminal fluid proteins in forensic testing. This will aid the development of 
more informed confirmatory interpretation guidelines for protein-based seminal fluid 
identification; inform forensic analysts about the probability of successful downstream 
genetic analysis; and address the inherent limitations of the serological approaches 
currently employed in case-working laboratories to detect the potential presence of seminal 
fluid in sexual assault-type evidentiary samples. In toto, this assay will provide the forensic 
community with powerful information to aid in the investigation of sexual assault. 
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5.4. Future Directions and Impact on the Criminal Justice System 
Past work comparing the proteomes of five body fluids commonly encountered in 
a case-working context resulted in the identification of multiple candidate high-specificity 
biomarkers for the confident identification of human body fluids.  The current studies have 
further expanded this body of knowledge. A triple Quadrupole Multiple Reaction 
Monitoring (QQQ-MRM) assay for the simultaneous confirmatory detection of protein 
biomarkers in six human body fluids was produced and developmentally validated. This 
multiplex QQQ-MRM assay will provide analysts with high confidence in the body fluid 
identification results obtained for a given stain. This is made possible by the use of not just 
one protein biomarker but rather on the presence of multiple proteins which in turn are 
based on multiple precursor and product ion pairs. Studies on casework-type samples have 
demonstrated the reliable performance of the assay; even with aged/weathered or otherwise 
chemically compromised samples. It was further demonstrated that the validated assay has 
the ability to overcome the inherent limitations of the antibody-based tests currently 
employed by case-working laboratories for the detection of seminal fluid. 
A seminal fluid specific monoplex assay was then developed specifically for the 
analysis of sexual assault samples with the goal of further enhancing the overall sensitivity 
for detecting trace levels of semen-specific target protein biomarkers.  The use of a 
monoplex QQQ-MRM assay that has been optimized for sensitivity and which can detect 
partially degraded seminal fluid markers will enhance the ability of forensic analysts to 
unambiguously detect semen in two significant ways. First, this approach will enable 
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analysts to report the confirmatory identification of semen in post-coital samples collected 
as much as 8 days after intercourse. Second, this approach may allow for the confirmation 
of seminal fluid in samples where there may be insufficient DNA to obtain an interpretable 
profile (e.g., in cases of vasectomy, lack of ejaculation or minimal sexual contact). In short, 
this will make it possible to obtain probative results from samples that might otherwise 
have yielded inconclusive or no results at all. This will provide the forensic and criminal 
justice communities in the United States and internationally with a powerful tool to aid the 
investigation and prosecution of sexual assault. 
The functionality of the monoplex method was then enhanced, to enable the 
absolute quantitation of targeted high-specificity seminal fluid protein biomarkers in the 
panel.  A major positive impact of now having a quantitative monoplex QQQ-MRM assay 
optimized for sensitivity is that it has enhanced the ability of forensic analysts to 
confidently detect seminal fluid well beyond the typical 1- to 2-day post-coital interval. By 
obtaining precise measurements of targeted protein levels and correlating these with the 
likelihood of successful DNA typing, practitioners will be able to leverage quantitative 
data on seminal fluid proteins in their decision making on downstream analyses for sexual 
assault swabs. This will enable practitioners to better identify for forensic investigators 
those items of evidence that are most likely to produce potentially probative results. It will 
also facilitate the more efficient allocation of resources by allowing analysts to focus their 
downstream genetic analyses efforts on those samples where protein quantitation results 
are predictive of successful male DNA typing. This will also have the effect of reducing 
the frequency with which analyst are asked to explain in a court of law the apparent 
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discrepancy between having an intimate sample that yields an interpretable male profile 
but for which serological testing was either not performed or failed to indicate the presence 
of seminal fluid. 
Future work should evaluate a fully-automated immunoaffinity Multiple Reaction 
Monitoring mass spectrometry (iMRM) method for the analysis of SAK samples.  The 
iMRM workflow uses custom antibodies to specifically enrich for targeted tryptic peptides.  
This would produce a highly purified final extract for analysis by LC-MSMS to reliably 
screen for both seminal fluid and saliva in SAK evidence.  In a proposal submitted to the 
US Armed Forces, the use of this iMRM proteomics strategy has been proposed to set 
statistically supported criteria for prioritizing SAK samples for genetic analysis based on 
preliminary data detailed in Chapter 5.  Both peptide and male-DNA quantitation 
thresholds would be established for predicting DNA typing success.  Using a separate 
dataset, type I and II error rates would be compared for the overall iMRM workflow to 
existing Y-screen strategies for SAK sample assessment using post-coital samples.  Front-
end sample solubilization and fractionation procedures can also be optimized.  The soak 
and spin methods employed in this research can be compared to new commercial products 
(Qiagen AllPrep) designed to fractionate DNA, RNA and protein to determine which 
methods produces the greatest chance of recovery for both protein and genetic material.  
Finally, a blind side-by-side assessment of novel serological workflows and strategies 
including proteomics, epigenetics and RNA-based techniques would provide the forensic 
community with a more informative look at the progress being made in each of these areas 
of research as compared to currently employed testing methodologies.  
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APPENDIX II:  CRITICAL VALUES FOLLOWING POST-HOC TUKEY TEST 
COMPARING UNSCHEDULED (METHOD 1) AND SCHEDULED (METHODS 




















































































































































































































































































































































































































































































































































































































































































































































































APPENDIX III:  QUALITATIVE MONOPLEX QQQ-MRM SEMINAL FLUID 
METHOD PARAMETERS 
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